| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | TA1045 | | |
| 24/7 EEG SubQ for epilepsy | MIB277 | | |
| 3C Patch for treating diabetic foot ulcers | HTG615 | | |
| Ab externo canaloplasty for primary open-angle glaucoma | HTG448 | | |
| Ab interno canaloplasty for open-angle glaucoma | HTG647 | | |
| Abaloparatide for treating osteoporosis after menopause | TA991 | | |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
| Abdominal aortic aneurysm: diagnosis and management | NG156 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer | TA1110 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Abortion care | NG140 | | |
| Abortion care | QS199 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Accuro for guiding epidural or spinal anaesthesia | MIB245 | | |
| AccuVein AV400 for vein visualisation | MIB6 | | |
| Acne vulgaris: management | NG198 | | |
| Acoramidis for treating transthyretin amyloidosis with cardiomyopathy | TA1121 | | |
| Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus | MIB5 | | |
| AcQMap for mapping the heart atria to target ablation treatment for arrhythmias | MIB246 | | |
| Actim Pancreatitis for diagnosing acute pancreatitis | MIB218 | | |
| Active B12 assay for diagnosing vitamin B12 deficiency | MIB40 | | |
| Acumen IQ sensor for predicting hypotension risk | MIB266 | | |
| Acute coronary syndromes | NG185 | | |
| Acute coronary syndromes in adults | QS68 | | |
| Acute heart failure | QS103 | | |
| Acute heart failure: diagnosis and management | CG187 | | |
| Acute kidney injury | QS76 | | |
| Acute kidney injury: prevention, detection and management | NG148 | | |
| Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) | QS210 | | |
| Acute upper gastrointestinal bleeding in adults | QS38 | | |
| Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
| Acutely ill adults in hospital: recognising and responding to deterioration | CG50 | | |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
| Adalimumab for treating moderate to severe plaque psoriasis | TA146 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
| Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
| AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis | MIB46 | | |
| Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I | HTG467 | | |
| Adrenal insufficiency: identification and management | NG243 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Advocacy services for adults with health and social care needs | NG227 | | |
| ADXBLADDER for detecting bladder cancer | MIB180 | | |
| Afamelanotide for treating erythropoietic protoporphyria | HST27 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Aflibercept for treating choroidal neovascularisation | TA486 | | |
| Aflibercept for treating diabetic macular oedema | TA346 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
| Age-related macular degeneration | NG82 | | |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
| AI technologies for detecting diabetic retinopathy | MIB265 | | |
| Air pollution: outdoor air quality and health | NG70 | | |
| Air pollution: outdoor air quality and health | QS181 | | |
| Airglove air warming system for venous access | MIB151 | | |
| Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions | MIB15 | | |
| Alair bronchial thermoplasty system for adults with severe difficult to control asthma | MIB71 | | |
| Alcohol interventions in secondary and further education | NG135 | | |
| Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension | HTG741 | | |
| Alcohol-use disorders: diagnosis and management | QS11 | | |
| Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
| Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | CG115 | | |
| Alcohol-use disorders: prevention | PH24 | | |
| Alcohol: preventing harmful use in the community | QS83 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Alere Afinion CRP for C-reactive protein testing in primary care | MIB81 | | |
| AlignRT for intracranial stereotactic radiosurgery | MIB147 | | |
| AlignRT in breast cancer radiotherapy | MIB157 | | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
| Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
| Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus | HTG165 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Alpha-Stim AID for anxiety disorders | HTG570 | | |
| Alteplase for treating acute ischaemic stroke | TA264 | | |
| Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
| AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas | MIB294 | | |
| Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy | MIB314 | | |
| Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy | MIB316 | | |
| Ambu aScope4 Broncho for use in unexpected difficult airways | HTG312 | | |
| Ambulight PDT for the treatment of non-melanoma skin cancer | HTG268 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1122 | | |
| AmnioSense for unexplained vaginal wetness in pregnancy | MIB198 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Anaphylaxis | QS119 | | |
| Anaphylaxis: assessment and referral after emergency treatment | CG134 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) | TA1029 | | |
| Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction | HTG402 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | TA1034 | | |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
| Antenatal and postnatal mental health | QS115 | | |
| Antenatal and postnatal mental health: clinical management and service guidance | CG192 | | |
| Antenatal care | NG201 | | |
| Antenatal care | QS22 | | |
| Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia | ES22 | | |
| Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections | ES32 | | |
| Antimicrobial prescribing: delafloxacin for community-acquired pneumonia | ES37 | | |
| Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults | ES40 | | |
| Antimicrobial prescribing: imipenem with cilastatin and relebactam | ES30 | | |
| Antimicrobial prescribing: meropenem with vaborbactam | ES21 | | |
| Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections | ES39 | | |
| Antimicrobial stewardship | QS121 | | |
| Antimicrobial stewardship: changing risk-related behaviours in the general population | NG63 | | |
| Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use | NG15 | | |
| Antisocial behaviour and conduct disorders in children and young people | QS59 | | |
| Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
| Antisocial personality disorder: prevention and management | CG77 | | |
| Anxiety disorders | QS53 | | |
| Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection | HTG634 | | |
| Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease | HTG689 | | |
| Aortic valve reconstruction with processed bovine pericardium | HTG461 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Apixaban for preventing venous thromboembolism after hip or knee replacement surgery | TA245 | | |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
| AposHealth for knee osteoarthritis | HTG671 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| Aptiva for painful diabetic neuropathy | MIB119 | | |
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | MIB315 | | |
| Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult | MIB53 | | |
| Archimedes for biopsy of suspected lung cancer | MIB211 | | |
| Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest | MIB112 | | |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
| Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
| Arteriovenous crossing sheathotomy for branch retinal vein occlusion | HTG211 | | |
| Arthroscopic femoro–acetabular surgery for hip impingement syndrome | HTG273 | | |
| Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis | HTG148 | | |
| Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee | HTG340 | | |
| Arthroscopic trochleoplasty for patellar instability | HTG328 | | |
| Artificial anal sphincter implantation | HTG39 | | |
| Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure | HTG459 | | |
| Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment | HTG746 | | |
| Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment | HTG695 | | |
| Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment | HTG760 | | |
| Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment | HTG739 | | |
| Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images | HTG687 | | |
| Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment | HTG696 | | |
| Artificial intelligence (AI)-derived software to help clinical decision making in stroke | HTG708 | | |
| Artificial intelligence for analysing chest CT images | MIB243 | | |
| Artificial intelligence for analysing CT brain scans | MIB207 | | |
| Artificial intelligence in mammography | MIB242 | | |
| Artificial iris insertion for acquired aniridia | HTG546 | | |
| Artificial iris insertion for congenital aniridia | HTG547 | | |
| Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis | HTG66 | | |
| Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis | HTG67 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Asfotase alfa for treating paediatric-onset hypophosphatasia | HST23 | | |
| Assessing motility of the gastrointestinal tract using a wireless capsule | HTG351 | | |
| Asthma | QS25 | | |
| Asthma pathway (BTS, NICE, SIGN) | NG244 | | |
| Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | NG245 | | |
| Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene | HST22 | | |
| ATEC system for vacuum-assisted breast biopsy | MIB43 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Atidarsagene autotemcel for treating metachromatic leukodystrophy | HST18 | | |
| Atogepant for preventing migraine | TA973 | | |
| Atopic eczema in under 12s: diagnosis and management | CG57 | | |
| Atopic eczema in under 12s | QS44 | | |
| Atrial fibrillation | QS93 | | |
| Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) | HTG353 | | |
| Atrial fibrillation: diagnosis and management | NG196 | | |
| Attention deficit hyperactivity disorder | QS39 | | |
| Attention deficit hyperactivity disorder: diagnosis and management | NG87 | | |
| Auditory brain stem implants | HTG65 | | |
| Autism | QS51 | | |
| Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
| Autism spectrum disorder in under 19s: recognition, referral and diagnosis | CG128 | | |
| Autism spectrum disorder in under 19s: support and management | CG170 | | |
| Autoimmune haemolytic anaemia: rituximab | ESUOM39 | | |
| Autologous blood injection for plantar fasciitis | HTG298 | | |
| Autologous blood injection for tendinopathy | HTG299 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
| Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy | HTG175 | | |
| Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers | HTG677 | | |
| Automated percutaneous mechanical lumbar discectomy | HTG88 | | |
| Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
| Avalglucosidase alfa for treating Pompe disease | TA821 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Avelumab with axitinib for untreated advanced renal cell carcinoma | TA1120 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
| Axonics sacral neuromodulation system for faecal incontinence | MIB259 | | |
| Axonics sacral neuromodulation system for treating refractory overactive bladder | HTG554 | | |
| Axumin for functional imaging of prostate cancer recurrence | MIB172 | | |
| Axxent electronic brachytherapy system for early stage breast cancer | MIB76 | | |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Babies, children and young people's experience of healthcare | NG204 | | |
| Bair Hugger for measuring core temperature during perioperative care | MIB99 | | |
| Balloon angioplasty of pulmonary vein stenosis in infants | HTG46 | | |
| Balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and children | HTG45 | | |
| Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis | HTG174 | | |
| Balloon catheter insertion for Bartholin's cyst or abscess | HTG204 | | |
| Balloon cryoablation for Barrett's oesophagus | HTG767 | | |
| Balloon cryoablation for squamous dysplasia of the oesophagus | HTG560 | | |
| Balloon dilatation of pulmonary valve stenosis | HTG40 | | |
| Balloon dilatation of systemic to pulmonary arterial shunts in children | HTG48 | | |
| Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children | HTG47 | | |
| Balloon dilation for chronic eustachian tube dysfunction | HTG534 | | |
| Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour | HTG744 | | |
| Balloon kyphoplasty for vertebral compression fractures | HTG108 | | |
| Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension | HTG410 | | |
| Balloon valvuloplasty for aortic valve stenosis in adults and children | HTG49 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal | HTG503 | | |
| Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
| BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis | MIB32 | | |
| Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment | HTG759 | | |
| Bedwetting in children and young people | QS70 | | |
| Bedwetting in under 19s | CG111 | | |
| Behaviour change: digital and mobile health interventions | NG183 | | |
| Behaviour change: general approaches | PH6 | | |
| Behaviour change: individual approaches | PH49 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis | TA1096 | | |
| Benralizumab for treating severe eosinophilic asthma | TA565 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
| Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | TA1087 | | |
| Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
| Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Bevacizumab gamma for treating wet age-related macular degeneration | TA1022 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse | HTG539 | | |
| Bile acid malabsorption: colesevelam | ESUOM22 | | |
| Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA918 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Bindex for investigating suspected osteoporosis | MIB106 | | |
| Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | HTG659 | | |
| Biodegradable subacromial spacer insertion for rotator cuff tears | HTG702 | | |
| Biomarker tests to help diagnose preterm labour in women with intact membranes | HTG476 | | |
| Biopatch for venous or arterial catheter sites | MIB117 | | |
| Bioprosthetic plug insertion for anal fistula | HTG528 | | |
| Bioresorbable stent implantation to treat coronary artery disease | HTG633 | | |
| Bipolar disorder in adults | QS95 | | |
| Bipolar disorder, psychosis and schizophrenia in children and young people | QS102 | | |
| Bipolar disorder: assessment and management | CG185 | | |
| Birch bark extract for treating epidermolysis bullosa | HST28 | | |
| Bisphosphonates for treating osteoporosis | TA464 | | |
| Bladder cancer | QS106 | | |
| Bladder cancer: diagnosis and management | NG2 | | |
| Bladder EpiCheck for detecting bladder cancer recurrence | MIB293 | | |
| BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume | MIB50 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | TA1049 | | |
| Blood transfusion | NG24 | | |
| Blood transfusion | QS138 | | |
| Bone-anchored cystourethropexy | HTG6 | | |
| Borderline personality disorder: recognition and management | CG78 | | |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
| Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
| Boston Keratoprosthesis Type I for corneal blindness | MIB91 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
| Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention | HTG685 | | |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
| Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision | HTG171 | | |
| Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
| Brain tumours (primary) and brain metastases in over 16s | QS203 | | |
| Breast cancer | QS12 | | |
| Breast reconstruction using lipomodelling after breast cancer treatment | HTG280 | | |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | | |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
| Brolucizumab for treating diabetic macular oedema | TA820 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Bronchial thermoplasty for severe asthma | HTG494 | | |
| Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing | NG117 | | |
| Bronchiolitis in children | QS122 | | |
| Bronchiolitis in children: diagnosis and management | NG9 | | |
| Bronchoscopic thermal vapour ablation for upper-lobe emphysema | HTG517 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Bulevirtide for treating chronic hepatitis D | TA896 | | |
| Burosumab for treating X-linked hypophosphataemia in adults | TA993 | | |
| Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
| Butterfly iQ+ for diagnostic ultrasound imaging | MIB254 | | |
| C3 glomerulopathy in the native kidney: eculizumab | ESUOM49 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Cabotegravir for preventing HIV-1 in adults and young people | TA1106 | | |
| Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Cabozantinib for treating medullary thyroid cancer | TA516 | | |
| Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
| CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease | MIB174 | | |
| Caesarean birth | NG192 | | |
| Caesarean birth | QS32 | | |
| Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
| Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over | NG36 | | |
| Cancer services for children and young people | QS55 | | |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
| Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
| Cannabis-based medicinal products | NG144 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer | TA100 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | | |
| Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Cardiac contractility modulation device implantation for heart failure | HTG520 | | |
| Cardiovascular disease prevention | PH25 | | |
| Cardiovascular disease: identifying and supporting people most at risk of dying early | PH15 | | |
| Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
| Cardiovascular risk assessment and lipid modification | QS100 | | |
| Care and support of people growing older with learning disabilities | NG96 | | |
| Care of dying adults in the last days of life | NG31 | | |
| Care of dying adults in the last days of life | QS144 | | |
| CareLink network service for remote monitoring of people with cardiac devices | MIB64 | | |
| Carfilzomib for previously treated multiple myeloma | TA657 | | |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment | HTG663 | | |
| Caris Molecular Intelligence for guiding cancer treatment | MIB120 | | |
| Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
| Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
| Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias | MIB276 | | |
| Carotid artery stent placement for symptomatic extracranial carotid stenosis | HTG258 | | |
| Cataracts in adults: management | NG77 | | |
| Catheterless oesophageal pH monitoring | HTG121 | | |
| Caval valve implantation for tricuspid regurgitation | HTG726 | | |
| Cefiderocol for treating severe drug-resistant gram-negative bacterial infections | AMR2 | | |
| Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections | AMR1 | | |
| Cellulitis and erysipelas: antimicrobial prescribing | NG141 | | |
| Cellvizio confocal endomicroscopy system for characterising pancreatic cysts | MIB69 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer | TA1108 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| CentriMag for heart failure | MIB92 | | |
| CerebAir for continuous EEG monitoring in intensive care | MIB279 | | |
| Cerebral palsy in adults | NG119 | | |
| Cerebral palsy in adults | QS191 | | |
| Cerebral palsy in children and young people | QS162 | | |
| Cerebral palsy in under 25s: assessment and management | NG62 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
| Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 | HST12 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic | MIB219 | | |
| Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges | NG11 | | |
| Child abuse and neglect | NG76 | | |
| Child abuse and neglect | QS179 | | |
| Child maltreatment: when to suspect maltreatment in under 18s | CG89 | | |
| Children's attachment | QS133 | | |
| Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care | NG26 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment | ESUOM7 | | |
| Chronic anal fissure: 2% topical diltiazem hydrochloride | ESUOM3 | | |
| Chronic anal fissure: botulinum toxin type A injection | ESUOM14 | | |
| Chronic heart failure in adults | QS9 | | |
| Chronic heart failure in adults: diagnosis and management | NG106 | | |
| Chronic kidney disease in adults | QS5 | | |
| Chronic kidney disease: assessment and management | NG203 | | |
| Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing | NG114 | | |
| Chronic obstructive pulmonary disease in adults | QS10 | | |
| Chronic obstructive pulmonary disease in over 16s: diagnosis and management | NG115 | | |
| Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
| Chronic urticaria: off-label doses of cetirizine | ESUOM31 | | |
| Chronic wounds: advanced wound dressings and antimicrobial dressings | ESMPB2 | | |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
| Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
| Circular stapled haemorrhoidectomy | HTG15 | | |
| Cirrhosis in over 16s: assessment and management | NG50 | | |
| Cladribine for treating active relapsing forms of multiple sclerosis | TA1053 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) | TA1105 | | |
| ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | HTG602 | | |
| ClearWay RX for drug delivery to coronary artery thrombotic lesions | MIB55 | | |
| clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia | MIB278 | | |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
| Clostridioides difficile infection: antimicrobial prescribing | NG199 | | |
| Clostridium difficile infection: risk with broad-spectrum antibiotics | ESMPB1 | | |
| Coban 2 for venous leg ulcers | MIB140 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
| Coeliac disease | QS134 | | |
| Coeliac disease: recognition, assessment and management | NG20 | | |
| Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | CG120 | | |
| Coexisting severe mental illness and substance misuse | QS188 | | |
| Coexisting severe mental illness and substance misuse: community health and social care services | NG58 | | |
| Coil embolisation of ruptured intracranial aneurysms | HTG64 | | |
| Coil embolisation of unruptured intracranial aneurysms | HTG63 | | |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
| Collagen injection for vocal cord augmentation | HTG79 | | |
| Collagen paste for closing an anal fistula | HTG512 | | |
| Colli-Pee for first void urine collection | MIB273 | | |
| ColonFlag for identifying people at risk of colorectal cancer | MIB142 | | |
| Colorectal cancer | NG151 | | |
| Colorectal cancer | QS20 | | |
| Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
| Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD) | HTG189 | | |
| Combined endoscopic and laparoscopic removal of colonic polyps | HTG354 | | |
| Combined oral contraception: nomegestrol/estradiol (Zoely) | ESNM28 | | |
| Community engagement: improving health and wellbeing | QS148 | | |
| Community engagement: improving health and wellbeing and reducing health inequalities | NG44 | | |
| Community pharmacies: promoting health and wellbeing | NG102 | | |
| Community pharmacies: promoting health and wellbeing | QS196 | | |
| Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) | HTG29 | | |
| Complicated intra-abdominal infections: ceftolozane/tazobactam | ESNM75 | | |
| Complicated urinary tract infections: ceftolozane/tazobactam | ESNM74 | | |
| Compression products for treating venous leg ulcers: late-stage assessment | HTG758 | | |
| Computed tomographic colonography (virtual colonoscopy) | HTG78 | | |
| Computed tomography-guided thermocoagulation of osteoid osteoma | HTG27 | | |
| Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) | TA1124 | | |
| Constipation in children and young people | QS62 | | |
| Constipation in children and young people: diagnosis and management | CG99 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
| Contraception | QS129 | | |
| Contraceptive services for under 25s | PH51 | | |
| Contrast-enhanced spectral mammography for breast cancer | MIB304 | | |
| Controlled drugs: safe use and management | NG46 | | |
| Cor-Knot for tying suture knots in valve surgery | MIB206 | | |
| Corneal endothelial transplantation | HTG195 | | |
| Corneal implants for keratoconus | HTG146 | | |
| Corneal implants for the correction of refractive error | HTG144 | | |
| Corneal inlay implantation for correction of presbyopia | HTG311 | | |
| Coronary revascularisation: Cangrelor | ESNM63 | | |
| Coronary sinus narrowing device implantation for refractory angina | HTG600 | | |
| Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis | HTG407 | | |
| CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes | MIB48 | | |
| Cough (acute): antimicrobial prescribing | NG120 | | |
| COVID-19 rapid guideline: haematopoietic stem cell transplantation | NG164 | | |
| COVID-19 rapid guideline: managing COVID-19 | NG191 | | |
| COVID-19 rapid guideline: managing the long-term effects of COVID-19 | NG188 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA1021 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Crohn's disease: management | NG129 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Cryoablation for atrial fibrillation in association with other cardiac surgery | HTG74 | | |
| Cryotherapy as a primary treatment for prostate cancer | HTG91 | | |
| Cryotherapy for chronic rhinitis | HTG692 | | |
| Cryotherapy for malignant endobronchial obstruction | HTG89 | | |
| Cryotherapy for recurrent prostate cancer | HTG71 | | |
| Cryotherapy for the treatment of liver metastases | HTG241 | | |
| Curos for preventing infections when using needleless connectors | HTG510 | | |
| Cyanoacrylate glue for hernia mesh fixation | MIB301 | | |
| Cyanoacrylate glue occlusion for varicose veins | HTG540 | | |
| Cyanoacrylate instillation for occlusion of parotid sinuses | HTG20 | | |
| CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack | HTG724 | | |
| Cystic fibrosis | QS168 | | |
| Cystic fibrosis: diagnosis and management | NG78 | | |
| Cytokine adsorption devices for treating respiratory failure in people with COVID-19 | MIB217 | | |
| Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis | HTG569 | | |
| CytoSorb for reducing risk of bleeding during cardiac surgery | MIB249 | | |
| CytoSorb therapy for sepsis | MIB87 | | |
| Cytosponge for detecting abnormal cells in the oesophagus | MIB240 | | |
| d-Nav insulin management app for type 2 diabetes | MIB285 | | |
| Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery | TA157 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Danis stent for acute oesophageal variceal bleeding | HTG574 | | |
| Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Dapagliflozin for treating chronic kidney disease | TA1075 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
| Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
| Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA1109 | | |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea | HTG672 | | |
| Decision making and mental capacity | QS194 | | |
| Decision-making and mental capacity | NG108 | | |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults | HTG577 | | |
| Deep brain stimulation for intractable trigeminal autonomic cephalalgias | HTG252 | | |
| Deep brain stimulation for Parkinson's disease | HTG7 | | |
| Deep brain stimulation for refractory chronic pain syndromes (excluding headache) | HTG253 | | |
| Deep brain stimulation for refractory epilepsy in adults | HTG550 | | |
| Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) | HTG122 | | |
| Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy | HTG300 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Delgocitinib for treating moderate to severe chronic hand eczema | TA1107 | | |
| Delirium in adults | QS63 | | |
| Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
| Dementia | QS184 | | |
| Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset | NG16 | | |
| Dementia: assessment, management and support for people living with dementia and their carers | NG97 | | |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
| Dental checks: intervals between oral health reviews | CG19 | | |
| Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) | TA1123 | | |
| Depression in adults | QS8 | | |
| Depression in adults with a chronic physical health problem: recognition and management | CG91 | | |
| Depression in adults: treatment and management | NG222 | | |
| Depression in children and young people | QS48 | | |
| Depression in children and young people: identification and management | NG134 | | |
| Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M | HTG292 | | |
| Desflurane for maintenance of anaesthesia | ES41 | | |
| Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) | HTG348 | | |
| Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
| Developing and updating local formularies | MPG1 | | |
| Developmental follow-up of children and young people born preterm | NG72 | | |
| Developmental follow-up of children and young people born preterm | QS169 | | |
| Devices for remote monitoring of Parkinson's disease | HTG657 | | |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
| Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
| Dexcom G6 for real-time continuous glucose monitoring | MIB233 | | |
| Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
| Diabetes in children and young people | QS125 | | |
| Diabetes in pregnancy | QS109 | | |
| Diabetes in pregnancy: management from preconception to the postnatal period | NG3 | | |
| Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) | ESNM64 | | |
| Diabetic foot problems: prevention and management | NG19 | | |
| Diabetic retinopathy: management and monitoring | NG242 | | |
| Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management | CG84 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain | MIB305 | | |
| Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment | HTG756 | | |
| Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment | HTG713 | | |
| Digital platforms to support cardiac rehabilitation: early value assessment | HTG761 | | |
| Digital self-help for eating disorders: early value assessment | HTG768 | | |
| Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) | HTG729 | | |
| Digital technologies for delivering multidisciplinary weight-management services: early value assessment | HTG700 | | |
| Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment | HTG766 | | |
| Digital technologies for managing non-specific low back pain: early value assessment | HTG712 | | |
| Digital technologies for the detection of melanoma | MIB311 | | |
| Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment | HTG718 | | |
| Digital technologies to support self-management of COPD: early value assessment | HTG736 | | |
| Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment | HTG748 | | |
| Digital ulcers: sildenafil | ESUOM42 | | |
| Digitally enabled therapies for adults with anxiety disorders: early value assessment | HTG676 | | |
| Digitally enabled therapies for adults with depression: early value assessment | HTG675 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
| Dinutuximab beta for treating neuroblastoma | TA538 | | |
| Direct C1 lateral mass screw for cervical spine stabilisation | HTG92 | | |
| Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant | HTG732 | | |
| Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
| Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education | NG213 | | |
| Distal iliotibial band lengthening for refractory greater trochanteric pain syndrome | HTG246 | | |
| Diverticular disease: diagnosis and management | NG147 | | |
| Division of ankyloglossia (tongue-tie) for breastfeeding | HTG95 | | |
| DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review | NR1 | | |
| DMD Care UK's guideline on respiratory care: NICE review | NR2 | | |
| DOAC Dipstick for detecting direct oral anticoagulants | MIB248 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| Domestic violence and abuse | QS116 | | |
| Domestic violence and abuse: multi-agency working | PH50 | | |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
| Donor milk banks: service operation | CG93 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | | |
| Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency | TA1117 | | |
| Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants | HTG276 | | |
| Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
| Drug allergy | QS97 | | |
| Drug allergy: diagnosis and management | CG183 | | |
| Drug misuse in over 16s: opioid detoxification | CG52 | | |
| Drug misuse in over 16s: psychosocial interventions | CG51 | | |
| Drug misuse prevention | QS165 | | |
| Drug misuse prevention: targeted interventions | NG64 | | |
| Drug use disorders in adults | QS23 | | |
| Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
| Drug-eluting stents for treating coronary artery disease: late-stage assessment | HTG747 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
| Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| DuraGraft for preserving vascular grafts | MIB184 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | TA1099 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1030 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | TA1090 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | HTG594 | | |
| Dyspepsia and gastro‑oesophageal reflux disease in adults | QS96 | | |
| E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta | HTG326 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab | ESNM13 | | |
| Early years: promoting health and wellbeing in under 5s | QS128 | | |
| EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | HTG611 | | |
| EarlySense for heart and respiratory monitoring and predicting patient deterioration | MIB49 | | |
| Eating disorders | QS175 | | |
| Eating disorders: recognition and treatment | NG69 | | |
| eazyplex SuperBug kits for detecting carbapenemase-producing organisms | MIB94 | | |
| Ectopic pregnancy and miscarriage | QS69 | | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NG126 | | |
| Eculizumab for treating atypical haemolytic uraemic syndrome | HST1 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over | TA1051 | | |
| Efgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | | |
| EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer | HTG316 | | |
| Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis | MIB93 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency | HST26 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease | HTG395 | | |
| Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease | HTG549 | | |
| Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer | HTG499 | | |
| Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults | HTG738 | | |
| Electrocautery cutting balloon treatment for pelviureteric junction obstruction | HTG205 | | |
| Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma | HTG305 | | |
| Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma | HTG333 | | |
| Electrohydraulic lithotripsy for difficult-to-treat bile duct stones | HTG583 | | |
| Electrosurgery (diathermy and coblation) for tonsillectomy | HTG96 | | |
| Electrotherapy for the treatment of haemorrhoids | HTG377 | | |
| Eliglustat for treating type 1 Gaucher disease | HST5 | | |
| Elosulfase alfa for treating mucopolysaccharidosis type 4A | HST19 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1023 | | |
| Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
| Emergency and acute medical care in over 16s | QS174 | | |
| Emergency and acute medical care in over 16s: service delivery and organisation | NG94 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
| End of life care for adults | QS13 | | |
| End of life care for adults: service delivery | NG142 | | |
| End of life care for infants, children and young people | QS160 | | |
| End of life care for infants, children and young people with life-limiting conditions: planning and management | NG61 | | |
| End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia | MIB10 | | |
| Endo-SPONGE for treating low rectal anastomotic leak | HTG605 | | |
| Endoanchoring systems in endovascular aortic aneurysm repair | HTG625 | | |
| Endoaortic balloon occlusion for cardiac surgery | HTG168 | | |
| Endobronchial nerve ablation for chronic obstructive pulmonary disease | HTG604 | | |
| Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions | HTG214 | | |
| Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses | HTG163 | | |
| Endobronchial valve insertion to reduce lung volume in emphysema | HTG457 | | |
| Endocuff Vision for assisting visualisation during colonoscopy | HTG514 | | |
| Endoluminal gastroplication for gastro-oesophageal reflux disease | HTG661 | | |
| Endometrial cryotherapy for menorrhagia | HTG101 | | |
| Endometriosis | QS172 | | |
| Endometriosis: diagnosis and management | NG73 | | |
| Endopyelotomy for pelviureteric junction obstruction | HTG206 | | |
| Endoscopic ablation for a pilonidal sinus | HTG507 | | |
| Endoscopic ablation for an anal fistula | HTG506 | | |
| Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease | HTG142 | | |
| Endoscopic axillary lymph node retrieval for breast cancer | HTG93 | | |
| Endoscopic balloon dilation for subglottic or tracheal stenosis | HTG614 | | |
| Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction | HTG731 | | |
| Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia | HTG406 | | |
| Endoscopic dacryocystorhinostomy | HTG68 | | |
| Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes | HTG721 | | |
| Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach | HTG612 | | |
| Endoscopic full thickness removal of non-lifting colonic polyps | HTG439 | | |
| Endoscopic injection of bulking agents for gastro-oesophageal reflux disease | HTG28 | | |
| Endoscopic laser foraminoplasty | HTG13 | | |
| Endoscopic mastectomy and endoscopic wide local excision for breast cancer | HTG188 | | |
| Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions | HTG232 | | |
| Endoscopic radical inguinal lymphadenectomy | HTG265 | | |
| Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia | HTG345 | | |
| Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease | HTG318 | | |
| Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus | HTG346 | | |
| Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence | HTG262 | | |
| Endoscopic saphenous vein harvest for coronary artery bypass grafting | HTG342 | | |
| Endoscopic sleeve gastroplasty for obesity | HTG711 | | |
| Endoscopic stapling of pharyngeal pouch | HTG8 | | |
| Endoscopic submucosal dissection of gastric lesions | HTG233 | | |
| Endoscopic submucosal dissection of lower gastrointestinal lesions | HTG212 | | |
| Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia | HTG228 | | |
| Endoscopic thoracic sympathectomy for primary facial blushing | HTG331 | | |
| Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb | HTG339 | | |
| Endoscopic transluminal pancreatic necrosectomy | HTG421 | | |
| Endoscopic transsphenoidal pituitary adenoma resection | HTG14 | | |
| Endoscopic ultrasound-guided biliary drainage for biliary obstruction | HTG673 | | |
| Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option | HTG683 | | |
| Endovascular atrial septostomy | HTG53 | | |
| Endovascular closure of atrial septal defect | HTG58 | | |
| Endovascular closure of patent ductus arteriosus | HTG59 | | |
| Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms | HTG524 | | |
| Endovascular stent insertion for intracranial atherosclerotic disease | HTG288 | | |
| Endovascular stent–graft placement in thoracic aortic aneurysms and dissections | HTG76 | | |
| Endovascular stent-grafting of popliteal aneurysms | HTG259 | | |
| Endovenous laser treatment of the long saphenous vein | HTG26 | | |
| Endovenous mechanochemical ablation for varicose veins | HTG414 | | |
| ENDURALIFE powered CRT-D devices for treating heart failure | HTG433 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | TA1097 | | |
| Entecavir for the treatment of chronic hepatitis B | TA153 | | |
| Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) | TA1118 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer | HTG714 | | |
| Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica | HTG425 | | |
| EpiFix for chronic wounds | MIB139 | | |
| Epilepsies in children, young people and adults | NG217 | | |
| Epilepsies in children, young people and adults | QS211 | | |
| Epiretinal brachytherapy for wet age-related macular degeneration | HTG279 | | |
| Episcissors-60 for mediolateral episiotomy | HTG538 | | |
| Epithelial radiofrequency ablation for Barrett's oesophagus | HTG219 | | |
| Eplontersen for treating hereditary transthyretin-related amyloidosis | TA1020 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment | MIB39 | | |
| Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor | TA1062 | | |
| Erectile dysfunction: Alprostadil cream | ESNM50 | | |
| Erectile dysfunction: avanafil | ESNM45 | | |
| Erenumab for preventing migraine | TA682 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
| Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| Etanercept and efalizumab for treating moderate to severe plaque psoriasis | TA103 | | |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B | TA989 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | MIB238 | | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
| Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation | HTG496 | | |
| Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant | HTG580 | | |
| Ex-vivo hepatic resection and reimplantation for liver cancer | HTG190 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |
| Excess winter deaths and illness and the health risks associated with cold homes | NG6 | | |
| EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing | HTG296 | | |
| eXroid for internal haemorrhoids | MIB201 | | |
| External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment | ESNM66 | | |
| Extracorporeal albumin dialysis for acute liver failure | HTG202 | | |
| Extracorporeal carbon dioxide removal for acute respiratory failure | HTG703 | | |
| Extracorporeal membrane oxygenation (ECMO) in postneonatal children | HTG17 | | |
| Extracorporeal membrane oxygenation for severe acute respiratory failure in adults | HTG260 | | |
| Extracorporeal photopheresis for Crohn's disease | HTG182 | | |
| Extracorporeal shockwave therapy for Achilles tendinopathy | HTG426 | | |
| Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder | HTG645 | | |
| Extracorporeal shockwave therapy for Peyronie's disease | HTG11 | | |
| Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome | HTG248 | | |
| Extracorporeal shockwave therapy for refractory plantar fasciitis | HTG200 | | |
| Extracorporeal shockwave therapy for refractory tennis elbow | HTG201 | | |
| Extracorporeal whole liver perfusion for acute liver failure | HTG573 | | |
| Extracranial to intracranial bypass for intracranial atherosclerosis | HTG452 | | |
| Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women | HTG434 | | |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
| Facial erythema of rosacea: brimonidine tartrate gel | ESNM43 | | |
| Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel | HTG320 | | |
| Faecal incontinence in adults | QS54 | | |
| Faecal incontinence in adults: management | CG49 | | |
| Faecal microbiota transplant for recurrent Clostridioides difficile infection | HTG638 | | |
| Faecal microbiota transplant for recurrent Clostridium difficile infection | HTG338 | | |
| Fallopian tube recanalisation by guidewire | HTG44 | | |
| Falloposcopy with coaxial catheter | HTG35 | | |
| Falls | QS86 | | |
| Falls: assessment and prevention in older people and in people 50 and over at higher risk | NG249 | | |
| Faltering growth | QS197 | | |
| Faltering growth: recognition and management of faltering growth in children | NG75 | | |
| Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
| Familial hypercholesterolaemia | QS41 | | |
| Familial hypercholesterolaemia: identification and management | CG71 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion | TA1004 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Fasciotens for abdominal wall closure | MIB321 | | |
| FebriDx for C-reactive protein and myxovirus resistance protein A testing | MIB224 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | | |
| Fertility problems | QS73 | | |
| Fertility problems: assessment and treatment | CG156 | | |
| Fetal alcohol spectrum disorder | QS204 | | |
| Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction | HTG131 | | |
| Fetal monitoring in labour | NG229 | | |
| Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction | HTG129 | | |
| Fetoscopic prenatal repair for open neural tube defects in the fetus | HTG536 | | |
| Fever in under 5s | QS64 | | |
| Fever in under 5s: assessment and initial management | NG143 | | |
| FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care | HTG682 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
| Flexible endoscopic treatment of a pharyngeal pouch | HTG367 | | |
| FLEXISEQ for osteoarthritis | MIB80 | | |
| Flu vaccination: increasing uptake | NG103 | | |
| Flu vaccination: increasing uptake | QS190 | | |
| Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
| Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
| Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment | HTG360 | | |
| Focal resurfacing implants to treat articular cartilage damage in the knee | HTG635 | | |
| Focal therapy using cryoablation for localised prostate cancer | HTG284 | | |
| Focal therapy using high-intensity focused ultrasound for localised prostate cancer | HTG667 | | |
| Foker technique for long-gap oesophageal atresia | HTG98 | | |
| Food allergy | QS118 | | |
| Food allergy in under 19s: assessment and diagnosis | CG116 | | |
| Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) | TA1078 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
| Fractures (complex): assessment and management | NG37 | | |
| Fractures (non-complex): assessment and management | NG38 | | |
| Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury | HTG568 | | |
| Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) | HTG619 | | |
| FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome | MIB281 | | |
| FreeStyle Libre for glucose monitoring | MIB110 | | |
| Fremanezumab for preventing migraine | TA764 | | |
| Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
| Fruquintinib for previously treated metastatic colorectal cancer | TA1079 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
| Functional electrical stimulation for drop foot of central neurological origin | HTG178 | | |
| Fungitell for antifungal treatment stratification | MIB118 | | |
| Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | | |
| GaitSmart rehabilitation exercise programme for gait and mobility issues | HTG716 | | |
| Galaxy UNYCO for temporary stabilisation of lower limb fractures | MIB166 | | |
| Galcanezumab for preventing migraine | TA659 | | |
| Gallstone disease | QS104 | | |
| Gallstone disease: diagnosis and management | CG188 | | |
| Gambling-related harms: identification, assessment and management | NG248 | | |
| gammaCore for cluster headache | HTG533 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over | TA1101 | | |
| Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | CG184 | | |
| Gastro-oesophageal reflux disease in children and young people: diagnosis and management | NG1 | | |
| Gastro-oesophageal reflux in children and young people | QS112 | | |
| Gastroelectrical stimulation for gastroparesis | HTG341 | | |
| Gastroparesis in adults: oral erythromycin | ESUOM13 | | |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
| Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment | HTG665 | | |
| Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
| Genicular artery embolisation for pain from knee osteoarthritis | HTG595 | | |
| Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
| Givosiran for treating acute hepatic porphyria | HST16 | | |
| Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
| Glaucoma: diagnosis and management | NG81 | | |
| Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | TA1113 | | |
| Golimumab for the treatment of psoriatic arthritis | TA220 | | |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
| Golimumab for treating active non-radiographic axial spondyloarthritis | TA497 | | |
| Gout: diagnosis and management | NG219 | | |
| Granulox for managing chronic non-healing wounds | MIB296 | | |
| GreenLight XPS for treating benign prostatic hyperplasia | HTG650 | | |
| Grenz rays therapy for inflammatory skin conditions | HTG151 | | |
| Guidance on the extraction of wisdom teeth | TA1 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Guidance on the use of coronary artery stents | TA71 | | |
| Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
| Guidance on the use of electroconvulsive therapy | TA59 | | |
| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
| Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
| Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
| Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
| Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
| Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
| Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment | HTG660 | | |
| Guselkumab for previously treated moderately to severely active Crohn's disease | TA1095 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
| Guselkumab for treating moderately to severely active ulcerative colitis | TA1094 | | |
| Haematological cancers | QS150 | | |
| Haematological cancers: improving outcomes | NG47 | | |
| Haemorrhoidal artery ligation | HTG218 | | |
| Hand allotransplantation | HTG254 | | |
| Harmful sexual behaviour among children and young people | NG55 | | |
| Head and neck cancer | QS146 | | |
| Head injury | QS74 | | |
| Head injury: assessment and early management | NG232 | | |
| Headaches in over 12s | QS42 | | |
| Headaches in over 12s: diagnosis and management | CG150 | | |
| HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
| Healthcare-associated infections | QS113 | | |
| Healthcare-associated infections: prevention and control | PH36 | | |
| Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
| HealthVCF for detecting vertebral compression fractures on CT scans | MIB267 | | |
| Healthy workplaces: improving employee mental and physical health and wellbeing | QS147 | | |
| Healthy.io test for home testing of urine albumin to creatinine ratio | MIB221 | | |
| Hearing loss in adults | QS185 | | |
| Hearing loss in adults: assessment and management | NG98 | | |
| Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices | HTG730 | | |
| Heart valve disease presenting in adults: investigation and management | NG208 | | |
| HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | HTG429 | | |
| Heavy menstrual bleeding | QS47 | | |
| Heavy menstrual bleeding: assessment and management | NG88 | | |
| Helge for detecting haemolysis | MIB225 | | |
| HemaClear for bloodless surgical field during limb surgery | MIB187 | | |
| Hemosep for cell salvage | MIB103 | | |
| Hepatitis B | QS65 | | |
| Hepatitis B (chronic): diagnosis and management | CG165 | | |
| Hepatitis B and C testing: people at risk of infection | PH43 | | |
| High dose rate brachytherapy for carcinoma of the cervix | HTG104 | | |
| High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer | HTG113 | | |
| High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery | HTG119 | | |
| High-intensity focused ultrasound for glaucoma | HTG527 | | |
| High-intensity focused ultrasound for prostate cancer | HTG70 | | |
| High-intensity focused ultrasound for symptomatic benign thyroid nodules | HTG504 | | |
| High-intensity focused ultrasound for symptomatic breast fibroadenoma | HTG449 | | |
| High-sensitivity troponin tests for the early rule out of NSTEMI | HTG552 | | |
| High-throughput non-invasive prenatal testing for fetal RHD genotype | HTG420 | | |
| Hip fracture in adults | QS16 | | |
| Hip fracture: management | CG124 | | |
| HIV testing: encouraging uptake | QS157 | | |
| HIV testing: increasing uptake among people who may have undiagnosed HIV | NG60 | | |
| Holmium laser prostatectomy | HTG5 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Home care for older people | QS123 | | |
| Home care: delivering personal care and practical support to older people living in their own homes | NG21 | | |
| Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome | HTG735 | | |
| HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer | MIB128 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Human and animal bites: antimicrobial prescribing | NG184 | | |
| Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
| Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
| HumiGard for preventing inadvertent perioperative hypothermia | HTG428 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates | HTG158 | | |
| Hyperhidrosis: oral glycopyrronium bromide | ESUOM16 | | |
| Hyperhidrosis: oxybutynin | ES10 | | |
| Hyperparathyroidism (primary): diagnosis, assessment and initial management | NG132 | | |
| Hypersexuality: fluoxetine | ESUOM46 | | |
| Hypertension in adults | QS28 | | |
| Hypertension in adults: diagnosis and management | NG136 | | |
| Hypertension in pregnancy | QS35 | | |
| Hypertension in pregnancy: diagnosis and management | NG133 | | |
| Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea | HTG455 | | |
| Hypothermia: prevention and management in adults having surgery | CG65 | | |
| Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids | HTG590 | | |
| Hysteroscopic metroplasty of a uterine septum for primary infertility | HTG363 | | |
| Hysteroscopic metroplasty of a uterine septum for recurrent miscarriage | HTG364 | | |
| i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department | MIB38 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
| Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
| Icare rebound tonometer to measure intraocular pressure | MIB57 | | |
| icobrain ms for active relapsing–remitting multiple sclerosis | MIB291 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over | TA1093 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) | TA1084 | | |
| Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
| Idelalisib for treating refractory follicular lymphoma | TA604 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Idiopathic pulmonary fibrosis in adults | QS79 | | |
| Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
| iFuse for treating chronic sacroiliac joint pain | HTG488 | | |
| Image-guided percutaneous laser ablation for primary and secondary liver tumours | HTG722 | | |
| Image-guided radiofrequency excision biopsy of breast lesions | HTG198 | | |
| Image-guided vacuum-assisted excision biopsy of benign breast lesions | HTG100 | | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Immune (idiopathic) thrombocytopenic purpura: rituximab | ESUOM35 | | |
| ImmunoCAP ISAC 112 for multiplex allergen testing | HTG413 | | |
| Immunoscore for predicting risk of colon cancer relapse | MIB269 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions | MIB89 | | |
| Impetigo: antimicrobial prescribing | NG153 | | |
| Implant insertion for prominent ears | HTG526 | | |
| Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke | HTG553 | | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
| Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes | HTG389 | | |
| Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes | HTG371 | | |
| Implantation of a duodenal–jejunal bypass sleeve for managing obesity | HTG323 | | |
| Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation | HTG369 | | |
| Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis | HTG366 | | |
| Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache | HTG378 | | |
| Implantation of accommodating intraocular lenses for cataract | HTG134 | | |
| Implantation of an opaque intraocular lens for intractable double vision | HTG185 | | |
| Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery | HTG170 | | |
| Implanted vagus nerve stimulation for treatment-resistant depression | HTG551 | | |
| Implanting a baroreceptor stimulation device for resistant hypertension | HTG387 | | |
| Improving outcomes for people with brain and other central nervous system tumours | CSG10 | | |
| Improving outcomes for people with sarcoma | CSG9 | | |
| Improving outcomes for people with skin tumours including melanoma | CSG8 | | |
| Improving outcomes in children and young people with cancer | CSG7 | | |
| Improving outcomes in head and neck cancers | CSG6 | | |
| Incisionless otoplasty | HTG283 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee | HTG203 | | |
| Indoor air quality at home | NG149 | | |
| Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage | HTG587 | | |
| Inducing labour | NG207 | | |
| Inducing labour | QS60 | | |
| Infantile haemangioma: topical timolol | ESUOM47 | | |
| Infection prevention and control | QS61 | | |
| Inflammatory bowel disease | QS81 | | |
| Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream | ESNM68 | | |
| Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
| Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
| Infliximab for treating moderate to severe plaque psoriasis | TA134 | | |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
| Infracoccygeal sacropexy using mesh to repair uterine prolapse | HTG443 | | |
| Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse | HTG442 | | |
| Injectable bulking agents for faecal incontinence | HTG135 | | |
| Inotersen for treating hereditary transthyretin amyloidosis | HST9 | | |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
| Insect bites and stings: antimicrobial prescribing | NG182 | | |
| Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula | HTG359 | | |
| Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section | HTG380 | | |
| Insertion of a magnetic bead band for faecal incontinence | HTG336 | | |
| Insertion of a subretinal prosthesis system for retinitis pigmentosa | HTG392 | | |
| Insertion of an annular disc implant at lumbar discectomy | HTG358 | | |
| Insertion of an epiretinal prosthesis for retinitis pigmentosa | HTG372 | | |
| Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction | HTG313 | | |
| Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction | HTG307 | | |
| Insertion of endobronchial nitinol coils to improve lung function in emphysema | HTG370 | | |
| Insertion of endobronchial valves for persistent air leaks | HTG306 | | |
| Insertion of hydrogel keratoprosthesis | HTG42 | | |
| Insertion of metal rib reinforcements to stabilise a flail chest wall | HTG234 | | |
| Insertion of pleuro–amniotic shunt for fetal pleural effusion | HTG123 | | |
| Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia | HTG329 | | |
| Integrated health and social care for people experiencing homelessness | NG214 | | |
| InterDry for intertrigo | MIB192 | | |
| Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
| Intermediate care including reablement | NG74 | | |
| Intermediate care including reablement | QS173 | | |
| Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment | HTG753 | | |
| Interspinous distraction procedures for lumbar spinal stenosis causing neurogenic claudication | HTG238 | | |
| Interstitial laser therapy for breast cancer | HTG55 | | |
| Interstitial laser therapy for fibroadenomas of the breast | HTG80 | | |
| Interstitial photodynamic therapy for malignant parotid tumours | HTG166 | | |
| Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
| Intralesional photocoagulation of subcutaneous congenital vascular disorders | HTG56 | | |
| Intramedullary distraction for lower limb lengthening | HTG613 | | |
| Intramedullary distraction for upper limb lengthening | HTG621 | | |
| Intramural urethral bulking procedures for stress urinary incontinence in women | HTG86 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease | HTG450 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries | HTG679 | | |
| Intranasal phototherapy for allergic rhinitis | HTG473 | | |
| Intraocular lens insertion for correction of refractive error, with preservation of the natural lens | HTG183 | | |
| Intraoperative blood cell salvage in obstetrics | HTG90 | | |
| Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer | HTG681 | | |
| Intraoperative fluorescence angiography for the evaluation of coronary artery bypass graft patency | HTG60 | | |
| Intraoperative nerve monitoring during thyroid surgery | HTG164 | | |
| Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy | HTG167 | | |
| Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer | HTG315 | | |
| Intrapartum care | NG235 | | |
| Intrapartum care | QS105 | | |
| Intrapartum care for women with existing medical conditions or obstetric complications and their babies | NG121 | | |
| Intrapartum care: existing medical conditions and obstetric complications | QS192 | | |
| Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome | HTG126 | | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | HTG707 | | |
| Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention | HTG740 | | |
| Intravenous fluid therapy in adults in hospital | CG174 | | |
| Intravenous fluid therapy in adults in hospital | QS66 | | |
| Intravenous fluid therapy in children and young people in hospital | NG29 | | |
| Intravenous fluid therapy in children and young people in hospital | QS131 | | |
| Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | HTG487 | | |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
| Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) | TA1102 | | |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria | TA1000 | | |
| Irreversible electroporation for primary liver cancer | HTG532 | | |
| Irreversible electroporation for treating liver metastases | HTG304 | | |
| Irreversible electroporation for treating pancreatic cancer | HTG437 | | |
| Irreversible electroporation for treating primary lung cancer and metastases in the lung | HTG302 | | |
| Irreversible electroporation for treating prostate cancer | HTG688 | | |
| Irreversible electroporation for treating renal cancer | HTG303 | | |
| Irritable bowel syndrome in adults | QS114 | | |
| Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable | TA1098 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
| iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia | MIB306 | | |
| Ivabradine for treating chronic heart failure | TA267 | | |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis | TA988 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA718 | | |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Jaundice in newborn babies under 28 days | CG98 | | |
| Jaundice in newborn babies under 28 days | QS57 | | |
| Joint distraction for ankle osteoarthritis | HTG393 | | |
| Joint distraction for knee osteoarthritis without alignment correction | HTG381 | | |
| Joint replacement (primary): hip, knee and shoulder | NG157 | | |
| Joint replacement (primary): hip, knee and shoulder | QS206 | | |
| KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment | HTG694 | | |
| KardiaMobile for detecting atrial fibrillation | HTG606 | | |
| Kendall DL for ECG monitoring in people having cardiac surgery | MIB177 | | |
| KODEX-EPD for cardiac imaging during ablation of arrhythmias | MIB260 | | |
| Kurin Lock for blood culture collection | HTG715 | | |
| L-Dex U400 for lymphoedema after breast cancer treatment | MIB111 | | |
| Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
| Laparo-endogastric surgery | HTG10 | | |
| Laparoscopic augmentation cystoplasty (including clam cystoplasty) | HTG207 | | |
| Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth | HTG500 | | |
| Laparoscopic cryotherapy for renal cancer | HTG271 | | |
| Laparoscopic cystectomy | HTG181 | | |
| Laparoscopic deroofing of simple renal cysts | HTG145 | | |
| Laparoscopic distal pancreatectomy | HTG130 | | |
| Laparoscopic gastrectomy for cancer | HTG172 | | |
| Laparoscopic gastric plication for the treatment of severe obesity | HTG293 | | |
| Laparoscopic helium plasma coagulation for the treatment of endometriosis | HTG112 | | |
| Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer | HTG229 | | |
| Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease | HTG654 | | |
| Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | HTG749 | | |
| Laparoscopic insertion of peritoneal dialysis catheter | HTG133 | | |
| Laparoscopic laser myomectomy | HTG9 | | |
| Laparoscopic live donor simple nephrectomy | HTG30 | | |
| Laparoscopic liver resection | HTG83 | | |
| Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina | HTG464 | | |
| Laparoscopic mobilisation of the greater omentum for breast reconstruction | HTG162 | | |
| Laparoscopic nephrectomy (including nephroureterectomy) | HTG84 | | |
| Laparoscopic nephrolithotomy and pyelolithotomy | HTG137 | | |
| Laparoscopic partial nephrectomy | HTG97 | | |
| Laparoscopic prostatectomy for benign prostatic obstruction | HTG176 | | |
| Laparoscopic pyeloplasty | HTG22 | | |
| Laparoscopic radical prostatectomy | HTG125 | | |
| Laparoscopic removal of uterine fibroids with power morcellation | HTG589 | | |
| Laparoscopic renal denervation for loin pain haematuria syndrome | HTG596 | | |
| Laparoscopic repair of abdominal aortic aneurysm | HTG147 | | |
| Laparoscopic retroperitoneal lymph node dissection for testicular cancer | HTG102 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Laparoscopic surgery for inguinal hernia repair | TA83 | | |
| Laparoscopic techniques for hysterectomy | HTG153 | | |
| Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain | HTG150 | | |
| Laparoscopic ventral mesh rectopexy for internal rectal prolapse | HTG475 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
| LARS for reconstructing damaged intra-articular cruciate knee ligaments | MIB30 | | |
| Laser correction of refractive error following non-refractive ophthalmic surgery | HTG256 | | |
| Laser lithotripsy for difficult-to-treat bile duct stones | HTG584 | | |
| Laser sheath removal of pacing leads | HTG36 | | |
| Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion | HTG161 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Lateral elbow resurfacing for arthritis | HTG591 | | |
| Lateral interbody fusion in the lumbar spine for low back pain | HTG431 | | |
| LATITUDE NXT Patient Management System for monitoring cardiac devices at home | MIB67 | | |
| Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care | HTG508 | | |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | HTG484 | | |
| Learning disabilities and behaviour that challenges: service design and delivery | NG93 | | |
| Learning disability: behaviour that challenges | QS101 | | |
| Learning disability: care and support of people growing older | QS187 | | |
| Learning disability: identifying and managing mental health problems | QS142 | | |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | | |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
| Leg ulcer infection: antimicrobial prescribing | NG152 | | |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
| Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
| Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
| Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
| Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
| Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over | HST33 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
| Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) | TA1082 | | |
| Leukapheresis for inflammatory bowel disease | HTG75 | | |
| Leukomed Sorbact for preventing surgical site infection | HTG567 | | |
| Lifelight First for monitoring vital signs | MIB213 | | |
| LiMAx system for assessing the functional capacity of the liver | MIB168 | | |
| Limited macular translocation for wet age-related macular degeneration | HTG215 | | |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | | |
| Linzagolix for treating symptoms of endometriosis | TA1067 | | |
| LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands | MIB29 | | |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
| Liposuction for chronic lipoedema | HTG618 | | |
| Liposuction for chronic lymphoedema | HTG622 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| Liraglutide for managing overweight and obesity | TA664 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) | TA987 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) | TA1083 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | | |
| Liver disease | QS152 | | |
| LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis | MIB317 | | |
| Living-donor liver transplantation | HTG390 | | |
| Living-donor lung transplantation for end-stage lung disease | HTG111 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Long-acting reversible contraception | CG30 | | |
| Looked-after children and young people | NG205 | | |
| Looked-after children and young people | QS31 | | |
| Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor | TA1103 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Low back pain and sciatica in over 16s | QS155 | | |
| Low back pain and sciatica in over 16s: assessment and management | NG59 | | |
| Low dose rate brachytherapy for localised prostate cancer | HTG81 | | |
| Low-energy contact X-ray brachytherapy for rectal cancer | HTG763 | | |
| Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures | HTG481 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing | HTG480 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing | HTG479 | | |
| Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy | HTG472 | | |
| Lower limb deep vein valve reconstruction for chronic deep venous incompetence | HTG141 | | |
| Lower urinary tract symptoms in men | QS45 | | |
| Lower urinary tract symptoms in men: management | CG97 | | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
| LQD Spray for treating acute and chronic wounds | MIB202 | | |
| Lumasiran for treating primary hyperoxaluria type 1 | HST25 | | |
| Lumbar infusion test for the investigation of normal pressure hydrocephalus | HTG169 | | |
| Lumbar subcutaneous shunt | HTG41 | | |
| Lumella point-of-care test for assessing pre-eclampsia risk | MIB287 | | |
| Lung cancer in adults | QS17 | | |
| Lung cancer: diagnosis and management | NG122 | | |
| Lung texture analysis for measuring interstitial lung diseases | MIB272 | | |
| Lung volume reduction surgery for advanced emphysema | HTG69 | | |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
| Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Lyme disease | NG95 | | |
| Lyme disease | QS186 | | |
| Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema | HTG717 | | |
| Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
| Macimorelin for diagnosing growth hormone deficiency | MIB320 | | |
| Macular translocation with 360° retinotomy for wet age-related macular degeneration | HTG216 | | |
| Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids | HTG12 | | |
| Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids | HTG277 | | |
| Magnetic resonance therapy for knee osteoarthritis | HTG588 | | |
| Magseed for locating impalpable breast cancer lesions | MIB236 | | |
| Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | HTG642 | | |
| Major trauma: assessment and initial management | NG39 | | |
| Major trauma: service delivery | NG40 | | |
| MammaTyper in vitro diagnostic test for determining breast cancer subtypes | MIB135 | | |
| Management of vomiting in children and young people with gastroenteritis: ondansetron | ESUOM34 | | |
| Managing medicines for adults receiving social care in the community | NG67 | | |
| Managing medicines in care homes | SC1 | | |
| Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | TA1073 | | |
| Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years | NG247 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
| Maximal cytoreductive surgery for advanced ovarian cancer | HTG668 | | |
| Mechanical clot retrieval for treating acute ischaemic stroke | HTG403 | | |
| Mechanical thrombectomy devices for acute ischaemic stroke | MIB153 | | |
| Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | CG76 | | |
| Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | NG215 | | |
| Medicines management for people receiving social care in the community | QS171 | | |
| Medicines management in care homes | QS85 | | |
| Medicines optimisation | QS120 | | |
| Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes | NG5 | | |
| Mega Soft Patient Return Electrode for use during monopolar electrosurgery | HTG290 | | |
| Melanoma: assessment and management | NG14 | | |
| Melatonin for treating sleep disorders in adults who are blind | ES38 | | |
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | HTG575 | | |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
| Memokath 051 Ureter stent for ureteric obstruction | HTG651 | | |
| Memokath-028, 044 and 045 stents for urethral obstruction | MIB123 | | |
| Meningitis (bacterial) and meningococcal disease | QS19 | | |
| Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
| Menopause | QS143 | | |
| Menopause: identification and management | NG23 | | |
| Mental health of adults in contact with the criminal justice system | NG66 | | |
| Mental health of adults in contact with the criminal justice system | QS163 | | |
| Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
| Mental wellbeing and independence for older people | QS137 | | |
| Mental wellbeing at work | NG212 | | |
| Mental wellbeing in over 65s: occupational therapy and physical activity interventions | PH16 | | |
| Mental wellbeing of older people in care homes | QS50 | | |
| Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers | HTG495 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mersey Burns for calculating fluid resuscitation volume when managing burns | MIB58 | | |
| Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
| Metatarsophalangeal joint replacement of the hallux | HTG87 | | |
| Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
| Metreleptin for treating lipodystrophy | HST14 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| microINR for anticoagulation therapy | MIB257 | | |
| Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma | HTG470 | | |
| Micropressure therapy for refractory Ménière's disease | HTG285 | | |
| Microwave ablation for atrial fibrillation in association with other cardiac surgery | HTG73 | | |
| Microwave ablation for primary or metastatic cancer in the lung | HTG609 | | |
| Microwave ablation for treating liver metastases | HTG409 | | |
| Microwave ablation of hepatocellular carcinoma | HTG138 | | |
| Midcarpal hemiarthroplasty for wrist arthritis | HTG529 | | |
| Middle meningeal artery embolisation for chronic subdural haematomas | HTG706 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
| Mifamurtide for the treatment of osteosarcoma | TA235 | | |
| Migalastat for treating Fabry disease | HST4 | | |
| Migraine prophylaxis: flunarizine | ESUOM33 | | |
| Mini-incision surgery for total knee replacement | HTG220 | | |
| Mini/micro screw implantation for orthodontic anchorage | HTG152 | | |
| Miniature lens system implantation for advanced age-related macular degeneration | HTG418 | | |
| Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab | ES1 | | |
| Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people | HTG684 | | |
| Minimally invasive oesophagectomy | HTG272 | | |
| Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones | MIB138 | | |
| Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus | HTG723 | | |
| Minimally invasive radical hysterectomy for early stage cervical cancer | HTG565 | | |
| Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain | HTG436 | | |
| Minimally invasive total hip replacement | HTG236 | | |
| Minimally invasive video‑assisted parathyroidectomy | HTG350 | | |
| Minimally invasive video-assisted thyroidectomy | HTG349 | | |
| MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes | MIB51 | | |
| Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) | TA1100 | | |
| Mirabegron for treating symptoms of overactive bladder | TA290 | | |
| MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery | MIB323 | | |
| MiraQ for assessing graft flow during coronary artery bypass graft surgery | HTG275 | | |
| Mirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Mitochondrial disorders in children: Co-enzyme Q10 | ES11 | | |
| MMprofiler for prognostic risk classification in multiple myeloma | MIB270 | | |
| Mobi-C for cervical disc replacement | MIB70 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| Molecular testing strategies for Lynch syndrome in people with colorectal cancer | HTG430 | | |
| MolecuLight i:X for wound imaging | MIB212 | | |
| Mollii suit for spasticity | MIB100 | | |
| Molnupiravir for treating COVID-19 | TA1056 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment | HTG257 | | |
| moorLDLS-BI for burn depth assessment | MIB251 | | |
| Mosaicplasty for symptomatic articular cartilage defects of the knee | HTG463 | | |
| Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
| Motor neurone disease | QS126 | | |
| Motor neurone disease: assessment and management | NG42 | | |
| MR-proADM test for use with clinical deterioration scores in cases of suspected infection | MIB195 | | |
| MRI fusion biopsy systems for diagnosing prostate cancer | HTG678 | | |
| MRI-based technologies for assessing non-alcoholic fatty liver disease | HTG655 | | |
| MRI-guided focused ultrasound subthalamotomy for treating Parkinson's | HTG734 | | |
| MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's | HTG733 | | |
| MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy | HTG541 | | |
| Multimorbidity | QS153 | | |
| Multimorbidity: clinical assessment and management | NG56 | | |
| Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis | HTG441 | | |
| Multiple pregnancy: twin and triplet pregnancies | QS46 | | |
| Multiple sclerosis | QS108 | | |
| Multiple sclerosis in adults: management | NG220 | | |
| myAIRVO2 for the treatment of chronic obstructive pulmonary disease | MIB161 | | |
| Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
| Myeloma: diagnosis and management | NG35 | | |
| Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
| Naldemedine for treating opioid-induced constipation | TA651 | | |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
| Naloxegol for treating opioid‑induced constipation | TA345 | | |
| Naltrexone for the management of opioid dependence | TA115 | | |
| Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
| Narcolepsy with or without cataplexy in adults: pitolisant | ES8 | | |
| Narrow band imaging for Barrett's oesophagus | MIB179 | | |
| Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry | MIB113 | | |
| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy | TA1126 | | |
| Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
| National Early Warning Score systems that alert to deteriorating adult patients in hospital | MIB205 | | |
| NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds | MIB208 | | |
| Natural Cycles for monitoring fertility | MIB244 | | |
| NaviCam for diagnosing gastrointestinal tract conditions | MIB104 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Needle and syringe programmes | PH52 | | |
| Needle fasciotomy for Dupuytren's contracture | HTG21 | | |
| Needle-free arterial non-injectable connector | MIB85 | | |
| Negative pressure wound therapy for the open abdomen | HTG321 | | |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | | |
| Neo Pedicle Screw System for spinal fusion surgery | MIB108 | | |
| Neon EEG electrode for EEG monitoring in newborns | MIB155 | | |
| Neonatal infection | QS75 | | |
| Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
| Neonatal parenteral nutrition | NG154 | | |
| Neonatal parenteral nutrition | QS205 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Nerve graft for corneal denervation | HTG629 | | |
| Nerve transfer to partially restore upper limb function in tetraplegia | HTG466 | | |
| Neuropad for detecting preclinical diabetic peripheral neuropathy | HTG486 | | |
| Neuropathic pain in adults: pharmacological management in non-specialist settings | CG173 | | |
| Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | HTG641 | | |
| Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
| New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners | HTG281 | | |
| Next-generation sequencing panel for solid tumour cancers in children | MIB133 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) | TA1111 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | | |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | | |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer | TA1127 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema | MIB144 | | |
| Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
| Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
| Non-Hodgkin's lymphoma: rituximab subcutaneous injection | ESNM46 | | |
| Non-rigid stabilisation techniques for the treatment of low back pain | HTG239 | | |
| Non-surgical reduction of the myocardial septum | HTG18 | | |
| Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death | HTG404 | | |
| Novii Wireless Patch System for maternal and fetal monitoring | MIB228 | | |
| NPi-200 for pupillary light reflex in critical care patients | MIB235 | | |
| Nusinersen for treating spinal muscular atrophy | TA588 | | |
| Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
| Nutrition support in adults | QS24 | | |
| O2matic PRO 100 for optimising oxygen treatment in respiratory conditions | MIB308 | | |
| Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | TA1116 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
| Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
| Obsessive-compulsive disorder and body dysmorphic disorder: treatment | CG31 | | |
| Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
| Occipital nerve stimulation for intractable chronic migraine | HTG310 | | |
| Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
| OCS Heart system for heart transplant | MIB86 | | |
| Odevixibat for treating progressive familial intrahepatic cholestasis | HST17 | | |
| ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot | MIB56 | | |
| Oesophago-gastric cancer | QS176 | | |
| Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Off-pump coronary artery bypass grafting | HTG249 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Older people with social care needs and multiple long-term conditions | NG22 | | |
| Older people: independence and mental wellbeing | NG32 | | |
| Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B | HST32 | | |
| Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Omalizumab for treating severe persistent allergic asthma | TA278 | | |
| Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal) | TA1061 | | |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
| Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | HST24 | | |
| Onasemnogene abeparvovec for treating spinal muscular atrophy | HST15 | | |
| One-piece closed bags for colostomies: late-stage assessment | HTG754 | | |
| Open femoro–acetabular surgery for hip impingement syndrome | HTG270 | | |
| Open prenatal repair for open neural tube defects in the fetus | HTG537 | | |
| Open reduction of slipped capital femoral epiphysis | HTG365 | | |
| Opioid dependence: buprenorphine prolonged-release injection (Buvidal) | ES19 | | |
| Optical coherence tomography to guide percutaneous coronary intervention | HTG332 | | |
| Optilume for anterior urethral strictures | MIB241 | | |
| Optilume for treating recurrent bulbar urethral strictures | HTG649 | | |
| Optowire for measuring fractional flow reserve | MIB199 | | |
| ORA G3 to measure corneal hysteresis | MIB150 | | |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
| Oral health for adults in care homes | NG48 | | |
| Oral health in care homes | QS151 | | |
| Oral health promotion in the community | QS139 | | |
| Oral health promotion: general dental practice | NG30 | | |
| Oral health: local authorities and partners | PH55 | | |
| Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
| OrganOx metra for liver transplant | MIB275 | | |
| Orthostatic hypotension due to autonomic dysfunction: midodrine | ESNM61 | | |
| Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | | |
| OSNA for colon cancer staging | MIB77 | | |
| Osteoarthritis in over 16s | QS87 | | |
| Osteoarthritis in over 16s: diagnosis and management | NG226 | | |
| Osteoporosis | QS149 | | |
| Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
| Otitis media (acute): antimicrobial prescribing | NG91 | | |
| Otitis media with effusion in under 12s | NG233 | | |
| Otovent nasal balloon for otitis media with effusion | MIB59 | | |
| Ovarian cancer | QS18 | | |
| Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment | ESUOM21 | | |
| Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
| Ovarian cancer: recognition and initial management | CG122 | | |
| Overweight and obesity management | QS212 | | |
| Overweight and obesity management | NG246 | | |
| OxyMask for delivering oxygen therapy | MIB160 | | |
| Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds | MIB11 | | |
| Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Paige Prostate for prostate cancer | MIB280 | | |
| Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Palforzia for treating peanut allergy in children and young people | TA769 | | |
| Palliative care for adults: strong opioids for pain relief | CG140 | | |
| Palliative photodynamic therapy for advanced oesophageal cancer | HTG132 | | |
| Pancreatic cancer | QS177 | | |
| Pancreatic cancer in adults: diagnosis and management | NG85 | | |
| Pancreatitis | NG104 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
| Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | HTG355 | | |
| Parkinson's disease | QS164 | | |
| Parkinson's disease in adults | NG71 | | |
| Partial left ventriculectomy (the Batista procedure) | HTG19 | | |
| Partial replacement of the meniscus of the knee using a biodegradable scaffold | HTG289 | | |
| Path Finder for freezing of gait in people with Parkinson's disease | MIB170 | | |
| Patient experience in adult NHS services | QS15 | | |
| Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
| Patient group directions | MPG2 | | |
| Patient Status Engine for wireless monitoring of vital signs | MIB271 | | |
| Patiromer for treating hyperkalaemia | TA623 | | |
| Patisiran for treating hereditary transthyretin amyloidosis | HST10 | | |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
| pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms | MIB222 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
| Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
| Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | | |
| Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
| Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
| Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer | TA1092 | | |
| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) | TA1125 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
| People's experience in adult social care services: improving the experience of care and support for people using adult social care services | NG86 | | |
| People's experience using adult social care services | QS182 | | |
| Peptest for diagnosing gastro‑oesophageal reflux | MIB31 | | |
| Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation | HTG186 | | |
| Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia | HTG187 | | |
| Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices | HTG251 | | |
| Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation | HTG286 | | |
| Percutaneous balloon valvuloplasty for fetal critical aortic stenosis | HTG471 | | |
| Percutaneous cementoplasty for palliative treatment of bony malignancies | HTG117 | | |
| Percutaneous closure of patent foramen ovale for recurrent migraine | HTG242 | | |
| Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers | HTG243 | | |
| Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events | HTG325 | | |
| Percutaneous coblation of the intervertebral disc for low back pain and sciatica | HTG397 | | |
| Percutaneous cryotherapy for renal cancer | HTG269 | | |
| Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | HTG698 | | |
| Percutaneous electrical nerve stimulation for refractory neuropathic pain | HTG308 | | |
| Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica | HTG398 | | |
| Percutaneous endoscopic colostomy | HTG105 | | |
| Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation | HTG417 | | |
| Percutaneous endoscopic laser cervical discectomy | HTG194 | | |
| Percutaneous endoscopic laser thoracic discectomy | HTG34 | | |
| Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access | HTG597 | | |
| Percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum | HTG114 | | |
| Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain | HTG652 | | |
| Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure | HTG599 | | |
| Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI | HTG515 | | |
| Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve | HTG585 | | |
| Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis | HTG617 | | |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | HTG492 | | |
| Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture | HTG422 | | |
| Percutaneous interlaminar endoscopic lumbar discectomy for sciatica | HTG411 | | |
| Percutaneous intradiscal laser ablation in the lumbar spine | HTG230 | | |
| Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain | HTG399 | | |
| Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease | HTG294 | | |
| Percutaneous laser coronary angioplasty | HTG250 | | |
| Percutaneous laser revascularisation for refractory angina pectoris | HTG193 | | |
| Percutaneous laser therapy for fetal tumours | HTG118 | | |
| Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg | HTG516 | | |
| Percutaneous mitral valve annuloplasty | HTG225 | | |
| Percutaneous mitral valve leaflet repair for mitral regurgitation | HTG513 | | |
| Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism | HTG222 | | |
| Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome | HTG235 | | |
| Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction | HTG297 | | |
| Percutaneous radiofrequency ablation for atrial fibrillation | HTG110 | | |
| Percutaneous radiofrequency ablation for primary or secondary lung cancers | HTG244 | | |
| Percutaneous radiofrequency ablation for renal cancer | HTG226 | | |
| Percutaneous retroperitoneal endoscopic necrosectomy | HTG255 | | |
| Percutaneous thoracic duct embolisation for persistent chyle leak | HTG666 | | |
| Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism | HTG705 | | |
| Percutaneous tibial nerve stimulation for faecal incontinence | HTG263 | | |
| Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis | HTG704 | | |
| Percutaneous transforaminal endoscopic lumbar discectomy for sciatica | HTG412 | | |
| Percutaneous transluminal renal sympathetic denervation for resistant hypertension | HTG662 | | |
| Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules | HTG646 | | |
| Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis | HTG501 | | |
| Percutaneous vertebroplasty | HTG3 | | |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
| Perioperative care in adults | NG180 | | |
| Peripheral arterial disease | QS52 | | |
| Peripheral arterial disease: diagnosis and management | CG147 | | |
| Peripheral nerve-field stimulation for chronic low back pain | HTG309 | | |
| Peristeen Plus transanal irrigation system for managing bowel dysfunction | HTG462 | | |
| PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | HTG282 | | |
| Permacol for treating anal fistulae | MIB105 | | |
| Permanent His-bundle pacemaker implantation for treating heart failure | HTG579 | | |
| Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome | HTG623 | | |
| Personality disorders: borderline and antisocial | QS88 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
| Pharyngeal electrical stimulation for neurogenic dysphagia | HTG709 | | |
| Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia | HTG319 | | |
| Photodynamic endometrial ablation | HTG23 | | |
| Photodynamic therapy for advanced bronchial carcinoma | HTG54 | | |
| Photodynamic therapy for Barrett's oesophagus | HTG223 | | |
| Photodynamic therapy for bile duct cancer | HTG82 | | |
| Photodynamic therapy for brain tumours | HTG184 | | |
| Photodynamic therapy for early-stage oesophageal cancer | HTG128 | | |
| Photodynamic therapy for localised inoperable endobronchial cancer | HTG85 | | |
| Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) | HTG99 | | |
| Photorefractive (laser) surgery for the correction of refractive errors | HTG107 | | |
| Phototherapeutic laser keratectomy for corneal surface irregularities | HTG231 | | |
| Phrenic nerve pacing for congenital central hypoventilation syndrome | HTG725 | | |
| Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury | HTG727 | | |
| Phrenic nerve transfer in brachial plexus injury | HTG322 | | |
| Physical activity and the environment | NG90 | | |
| Physical activity for children and young people | PH17 | | |
| Physical activity in the workplace | PH13 | | |
| Physical activity: brief advice for adults in primary care | PH44 | | |
| Physical activity: encouraging activity in the community | QS183 | | |
| Physical activity: exercise referral schemes | PH54 | | |
| Physical activity: for NHS staff, patients and carers | QS84 | | |
| Physical activity: walking and cycling | PH41 | | |
| Physical health of people in prison | NG57 | | |
| Physical health of people in prisons | QS156 | | |
| PICO negative pressure wound dressings for closed surgical incisions | HTG509 | | |
| Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms | HTG287 | | |
| Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
| Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
| PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection | MIB200 | | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
| Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) | HTG199 | | |
| Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer | MIB137 | | |
| PLASMA system with button electrode for electrovaporisation of the prostate | MIB274 | | |
| Platelet-rich plasma injections for knee osteoarthritis | HTG497 | | |
| PleuraFlow Active Clearance Technology for maintaining chest tube patency | MIB125 | | |
| PLGF-based testing to help diagnose suspected preterm pre-eclampsia | HTG630 | | |
| Plus Sutures for preventing surgical site infection | HTG586 | | |
| Pneumonia: diagnosis and management | NG250 | | |
| Pneumonia: diagnosis and management | QS110 | | |
| PneuX to prevent ventilator-associated pneumonia | HTG543 | | |
| Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease | MIB132 | | |
| Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast | HTG530 | | |
| Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment | HTG674 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
| Polycystic ovary syndrome: metformin in women not planning pregnancy | ESUOM6 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
| Post-traumatic stress disorder | NG116 | | |
| Postnatal care | NG194 | | |
| Postnatal care | QS37 | | |
| Postural hypotension in adults: fludrocortisone | ESUOM20 | | |
| Pouchitis: rifaximin | ESUOM30 | | |
| Powered microdebrider turbinoplasty for inferior turbinate hypertrophy | HTG347 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
| Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
| PredictSURE IBD and IBDX to guide treatment of Crohn's disease | HTG610 | | |
| PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis | MIB313 | | |
| Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors | CG110 | | |
| Premature ejaculation: dapoxetine | ESNM40 | | |
| Preoperative high dose rate brachytherapy for rectal cancer | HTG383 | | |
| Pressure ulcers | QS89 | | |
| Pressure ulcers: prevention and management | CG179 | | |
| Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | HTG558 | | |
| Preterm labour and birth | NG25 | | |
| Preterm labour and birth | QS135 | | |
| Prevena incision management system for closed surgical incisions | MIB173 | | |
| Preventing excess winter deaths and illness associated with cold homes | QS117 | | |
| Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate | ESUOM4 | | |
| Preventing suicide in community and custodial settings | NG105 | | |
| Preventing unintentional injury in under 15s | QS107 | | |
| Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron | ESNM69 | | |
| Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab | ESUOM44 | | |
| Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) | HTG386 | | |
| Processed nerve allografts to repair peripheral nerve discontinuities | HTG454 | | |
| ProciseDx point-of-care platform for inflammatory bowel disease | MIB302 | | |
| ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment | HTG664 | | |
| Prolaris gene expression assay for assessing long-term risk of prostate cancer progression | MIB65 | | |
| PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes | MIB312 | | |
| Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups | QS167 | | |
| Promoting tolerance of enteral feeds in children and young people: domperidone | ESUOM18 | | |
| Prontosan for treating acute and chronic wounds | HTG616 | | |
| Proov Confirm for ovulation confirmation | MIB322 | | |
| PROPATEN heparin-bonded vascular graft for peripheral arterial disease | MIB42 | | |
| PROPEL sinus implants for maintaining sinus patency after surgery | MIB253 | | |
| Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
| Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG469 | | |
| Prostate cancer | QS91 | | |
| Prostate cancer: diagnosis and management | NG131 | | |
| Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG639 | | |
| Prostatitis (acute): antimicrobial prescribing | NG110 | | |
| Prosthetic intervertebral disc replacement in the cervical spine | HTG217 | | |
| Prosthetic intervertebral disc replacement in the lumbar spine | HTG197 | | |
| Prucalopride for the treatment of chronic constipation in women | TA211 | | |
| Psoriasis | QS40 | | |
| Psoriasis: assessment and management | CG153 | | |
| Psychosis and schizophrenia in adults | QS80 | | |
| Psychosis and schizophrenia in adults: prevention and management | CG178 | | |
| Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
| Pulmonary artery pressure technologies for remote monitoring of chronic heart failure | HTG769 | | |
| Pulmonary sarcoidosis: infliximab | ES2 | | |
| PulmoVista 500 for monitoring ventilation in critical care | MIB203 | | |
| Pulsed-field ablation for atrial fibrillation | HTG755 | | |
| Pyelonephritis (acute): antimicrobial prescribing | NG111 | | |
| QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography | HTG571 | | |
| QTUG for assessing falls risk and frailty | MIB73 | | |
| Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care | HTG690 | | |
| QuickChange Incontinence Wrap for urinary incontinence in men | MIB237 | | |
| QuikRead go for C-reactive protein testing in primary care | MIB78 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Radially emitting laser fibre treatment of an anal fistula | HTG505 | | |
| Radiation dose monitoring software for medical imaging with ionising radiation | MIB127 | | |
| Radiation therapy for early Dupuytren's disease | HTG427 | | |
| Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases | HTG670 | | |
| Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery | HTG72 | | |
| Radiofrequency ablation for colorectal liver metastases | HTG208 | | |
| Radiofrequency ablation for gastric antral vascular ectasia | HTG373 | | |
| Radiofrequency ablation for palliation of painful spinal metastases | HTG669 | | |
| Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma | HTG394 | | |
| Radiofrequency ablation of hepatocellular carcinoma | HTG1 | | |
| Radiofrequency ablation of the soft palate for snoring | HTG327 | | |
| Radiofrequency ablation of varicose veins | HTG2 | | |
| Radiofrequency cold ablation for respiratory papillomatosis | HTG295 | | |
| Radiofrequency denervation for osteoarthritic knee pain | HTG686 | | |
| Radiofrequency tissue reduction for turbinate hypertrophy | HTG343 | | |
| Radiofrequency treatment for haemorrhoids | HTG447 | | |
| Radiofrequency valvotomy for pulmonary atresia | HTG57 | | |
| Radiofrequency-assisted liver resection | HTG136 | | |
| Radiotherapy for age-related macular degeneration | HTG24 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
| Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
| Rapid tests for group A streptococcal infections in people with a sore throat | HTG531 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
| Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
| Reducing sexually transmitted infections | NG221 | | |
| Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues | HTG535 | | |
| Refractory extrapulmonary sarcoidosis: infliximab | ES4 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
| Rehabilitation after critical illness in adults | CG83 | | |
| Rehabilitation after critical illness in adults | QS158 | | |
| Rehabilitation after traumatic injury | NG211 | | |
| Rehabilitation for adults with complex psychosis | NG181 | | |
| Rehabilitation for chronic neurological disorders including acquired brain injury | NG252 | | |
| Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia | HTG519 | | |
| Relugolix for treating hormone-sensitive prostate cancer | TA995 | | |
| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
| Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | TA1057 | | |
| Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
| Remote ECG interpretation consultancy services for cardiovascular disease | MIB152 | | |
| Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment | HTG693 | | |
| Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause | HTG640 | | |
| Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis | ES35 | | |
| Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis | ES29 | | |
| Renal and ureteric stones | QS195 | | |
| Renal and ureteric stones: assessment and management | NG118 | | |
| Renal replacement therapy and conservative management | NG107 | | |
| Renal replacement therapy services for adults | QS72 | | |
| RenalSense Clarity RMS for acute kidney injury | MIB256 | | |
| Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma | HTG576 | | |
| Repetitive transcranial magnetic stimulation for depression | HTG396 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| RespiraSense for continuously monitoring respiratory rate | MIB299 | | |
| Restless legs syndrome: Oxycodone/naloxone prolonged release | ESNM67 | | |
| ReStore Soft Exo-Suit for gait rehabilitation | MIB239 | | |
| Retrobulbar irradiation for thyroid eye disease | HTG94 | | |
| Retrograde urethral sphincterometry | HTG109 | | |
| Reversal of the anticoagulant effect of dabigatran: idarucizumab | ESNM73 | | |
| Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | HTG545 | | |
| Rheumatoid arthritis in adults: management | NG100 | | |
| Rheumatoid arthritis in over 16s | QS33 | | |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence | TA1086 | | |
| Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease | MIB109 | | |
| Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
| Rimegepant for preventing migraine | TA906 | | |
| Rimegepant for treating migraine | TA919 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
| Risankizumab for treating moderately to severely active ulcerative colitis | TA998 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
| Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
| Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma | TA137 | | |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
| Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
| Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery | TA170 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
| Robot-assisted kidney transplant | HTG468 | | |
| Robot-assisted surgery for orthopaedic procedures: early value assessment | HTG743 | | |
| Robot-assisted surgery for soft tissue procedures: early value assessment | HTG742 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
| Romosozumab for treating severe osteoporosis | TA791 | | |
| Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
| Routine preoperative tests for elective surgery | NG45 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| RT300 for spinal cord injury rehabilitation | MIB169 | | |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over | TA1088 | | |
| Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over | TA1054 | | |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| S-Cath System for suprapubic catheterisation | MIB68 | | |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) | TA1089 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Sacral nerve stimulation for faecal incontinence | HTG61 | | |
| Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention | HTG391 | | |
| Sacral nerve stimulation for urge incontinence and urgency-frequency | HTG37 | | |
| Sacrocolpopexy using mesh to repair vaginal vault prolapse | HTG444 | | |
| Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse | HTG435 | | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
| Safe midwifery staffing for maternity settings | NG4 | | |
| Safe staffing for nursing in adult inpatient wards in acute hospitals | SG1 | | |
| Safeguarding adults in care homes | NG189 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Sarcoma | QS78 | | |
| Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) | TA1104 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Schizophrenia: lurasidone | ESNM48 | | |
| Schizophrenia: omega-3 fatty acid medicines | ESUOM19 | | |
| Scleral expansion surgery for presbyopia | HTG43 | | |
| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
| Sebelipase alfa for treating Wolman disease | HST30 | | |
| Secca System for faecal incontinence | MIB66 | | |
| Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing | NG190 | | |
| Secondary prevention after a myocardial infarction | QS99 | | |
| Secukinumab for treating active ankylosing spondylitis | TA407 | | |
| Secukinumab for treating active non-radiographic axial spondyloarthritis | TA719 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| SecurAcath for securing cerebrospinal fluid catheters | MIB107 | | |
| SecurAcath for securing percutaneous catheters | HTG440 | | |
| SecurePort IV tissue adhesive for use with percutaneous catheters | MIB288 | | |
| Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care | HTG607 | | |
| Sedation in under 19s: using sedation for diagnostic and therapeutic procedures | CG112 | | |
| SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | HTG598 | | |
| Selective dorsal rhizotomy for spasticity in cerebral palsy | HTG245 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver | HTG720 | | |
| Selective internal radiation therapy for primary hepatocellular carcinoma | HTG314 | | |
| Selective internal radiation therapy for unresectable colorectal metastases in the liver | HTG542 | | |
| Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma | HTG489 | | |
| Selective peripheral denervation for cervical dystonia | HTG51 | | |
| Self-expanding implant insertion into the intersphincteric space for faecal incontinence | HTG564 | | |
| Self‑harm | QS34 | | |
| Self-harm: assessment, management and preventing recurrence | NG225 | | |
| Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
| Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments | TA970 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over | HST20 | | |
| SEM Scanner 200 for preventing pressure ulcers | HTG556 | | |
| Semaglutide for managing overweight and obesity | TA875 | | |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
| Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain | HTG498 | | |
| SepsiTest assay for rapidly identifying bloodstream bacteria and fungi | HTG400 | | |
| Septostomy with or without amnioreduction for the treatment of twin-to-twin transfusion syndrome | HTG127 | | |
| Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children | HTG149 | | |
| Serious eye disorders | QS180 | | |
| Service user experience in adult mental health services | QS14 | | |
| Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services | CG136 | | |
| Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children | MIB163 | | |
| Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome | HST31 | | |
| Setmelanotide for treating obesity caused by LEPR or POMC deficiency | HST21 | | |
| Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide | ES5 | | |
| Sexual health | QS178 | | |
| Sexually transmitted infections: condom distribution schemes | NG68 | | |
| Shared decision making | NG197 | | |
| Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia | MIB22 | | |
| Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery | HTG115 | | |
| Shoulder resurfacing arthroplasty | HTG227 | | |
| Sickle cell disease | QS58 | | |
| Sickle cell disease: managing acute painful episodes in hospital | CG143 | | |
| Signatera for detecting molecular residual disease from solid tumour cancers | MIB307 | | |
| SimpliCT laser-guided needle placement in interventional radiology | MIB98 | | |
| Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity | HTG423 | | |
| Single‑incision laparoscopic cholecystectomy | HTG361 | | |
| Single-incision short sling mesh insertion for stress urinary incontinence in women | HTG419 | | |
| Single-port laparoscopic nephrectomy | HTG278 | | |
| Single-step scaffold insertion for repairing symptomatic chondral knee defects | HTG728 | | |
| Sinus tarsi implant insertion for mobile flatfoot | HTG196 | | |
| Sinusitis (acute): antimicrobial prescribing | NG79 | | |
| Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Skin cancer | QS130 | | |
| Skin cancer prevention | PH32 | | |
| Skin involvement in systemic sclerosis: rituximab | ES7 | | |
| Sleepio to treat insomnia and insomnia symptoms | HTG624 | | |
| Slide sheets for moving or repositioning a person: late-stage assessment | HTG745 | | |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
| Smart One for measuring lung function | MIB96 | | |
| Smart Peak Flow for monitoring asthma | MIB282 | | |
| Smartinhaler for asthma | MIB90 | | |
| Smoking: reducing and preventing tobacco use | QS82 | | |
| Social and emotional wellbeing: early years | PH40 | | |
| Social anxiety disorder: recognition, assessment and treatment | CG159 | | |
| Social care for older people with multiple long-term conditions | QS132 | | |
| Social work with adults experiencing complex needs | NG216 | | |
| Social, emotional and mental wellbeing in primary and secondary education | NG223 | | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
| Sofosbuvir for treating chronic hepatitis C | TA330 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
| Soft-palate implants for obstructive sleep apnoea | HTG155 | | |
| Soft-palate implants for simple snoring | HTG154 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years | TA1066 | | |
| Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult | MIB54 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids | MIB255 | | |
| SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver | HTG291 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Sore throat (acute): antimicrobial prescribing | NG84 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Sparsentan for treating primary IgA nephropathy | TA1074 | | |
| Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome | MIB223 | | |
| Spasticity in under 19s: management | CG145 | | |
| Specialist neonatal respiratory care for babies born preterm | NG124 | | |
| Specialist neonatal respiratory care for babies born preterm | QS193 | | |
| Spectra Optia for automatic red blood cell exchange in people with sickle cell disease | HTG405 | | |
| Spesolimab for treating generalised pustular psoriasis flares | TA1070 | | |
| Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
| Spinal injury: assessment and initial management | NG41 | | |
| Spinal metastases and metastatic spinal cord compression | NG234 | | |
| Spinal metastases and metastatic spinal cord compression | QS56 | | |
| Spiral Flow peripheral vascular graft for treating peripheral arterial disease | MIB34 | | |
| Spondyloarthritis | QS170 | | |
| Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
| Stable angina | QS21 | | |
| Stable angina: management | CG126 | | |
| Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
| Stapled transanal rectal resection for obstructed defaecation syndrome | HTG224 | | |
| Stent insertion for bleeding oesophageal varices | HTG261 | | |
| Stent placement for vena caval obstruction | HTG50 | | |
| Stent-graft placement in abdominal aortic aneurysm | HTG106 | | |
| Stereotactic radiosurgery for trigeminal neuralgia | HTG608 | | |
| Sternal Talon for sternal closure in cardiothoracic surgery | MIB88 | | |
| Stimulated graciloplasty for faecal incontinence | HTG103 | | |
| Stockholm3 for prostate cancer screening | MIB303 | | |
| StoneChecker for kidney stone evaluation | MIB171 | | |
| Stretta System for gastro-oesophageal reflux disease | MIB74 | | |
| Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency | HST7 | | |
| Stroke and transient ischaemic attack in over 16s: diagnosis and initial management | NG128 | | |
| Stroke in adults | QS2 | | |
| Stroke rehabilitation in adults | NG236 | | |
| Structural neuroimaging in first-episode psychosis | TA136 | | |
| Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | NG228 | | |
| Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis | HTG490 | | |
| Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death | HTG460 | | |
| Subfascial endoscopic perforator vein surgery | HTG32 | | |
| Subthalamotomy for Parkinson's disease | HTG38 | | |
| Suction diathermy adenoidectomy | HTG209 | | |
| Suicide prevention | QS189 | | |
| Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
| Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
| Sunlight exposure: risks and benefits | NG34 | | |
| Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis | HTG626 | | |
| superDimension Navigation System to help diagnostic sampling of peripheral lung lesions | MIB194 | | |
| Superficial venous arterialisation for chronic limb threatening ischaemia | HTG637 | | |
| Superior capsular augmentation for massive rotator cuff tears | HTG477 | | |
| Superior rectal artery embolisation for haemorrhoids | HTG485 | | |
| SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea | MIB190 | | |
| Supporting adult carers | NG150 | | |
| Supporting adult carers | QS200 | | |
| Supraorbital minicraniotomy for intracranial aneurysm | HTG52 | | |
| Surgical site infection | QS49 | | |
| Surgical site infections: prevention and treatment | NG125 | | |
| Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
| Suspected cancer | QS124 | | |
| Suspected cancer: recognition and referral | NG12 | | |
| Suspected neurological conditions: recognition and referral | NG127 | | |
| Suspected neurological conditions: recognition and referral | QS198 | | |
| Suspected sepsis in over 16s | QS213 | | |
| Suspected sepsis in people aged 16 or over: recognition, assessment and early management | NG253 | | |
| Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management | NG255 | | |
| Suspected sepsis in under 16s: recognition, diagnosis and early management | NG254 | | |
| Suture fixation of acute disruption of the distal tibiofibular syndesmosis | HTG374 | | |
| Sutureless aortic valve replacement for aortic stenosis | HTG483 | | |
| Swallowable gastric balloon capsule for weight loss | HTG561 | | |
| Symptoms of peripheral arterial disease: ramipril | ESUOM45 | | |
| SYNE-COV for predicting COVID-19 outcomes | MIB264 | | |
| Synergo for non-muscle-invasive bladder cancer | HTG601 | | |
| Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) | HTG627 | | |
| t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes | MIB227 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
| TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation | MIB60 | | |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA984 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1114 | | |
| Targeted muscle reinnervation for managing limb amputation pain | HTG750 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA1128 | | |
| Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments | TA1091 | | |
| TearLab osmolarity system for diagnosing dry eye disease | MIB47 | | |
| Tebentafusp for treating advanced uveal melanoma | TA1027 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Tegaderm CHG securement dressing for vascular access sites | MIB231 | | |
| Tegaderm CHG securement dressing for vascular access sites in critically ill adults | HTG379 | | |
| Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
| Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects | HTG357 | | |
| Temperature control to improve neurological outcomes after cardiac arrest | HTG710 | | |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
| Tenecteplase for treating acute ischaemic stroke | TA990 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
| Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) | HTG191 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
| Testing strategies for Lynch syndrome in people with endometrial cancer | HTG557 | | |
| Tests in secondary care to identify people at high risk of ovarian cancer | HTG453 | | |
| Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) | HTG544 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma | MIB8 | | |
| The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy | MIB19 | | |
| The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation | MIB18 | | |
| The Debrisoft monofilament debridement pad for use in acute or chronic wounds | HTG334 | | |
| The EOS 2D/3D imaging system | HTG274 | | |
| The Epidrum for aiding access to the epidural space | MIB23 | | |
| The geko device for reducing the risk of venous thromboembolism | HTG344 | | |
| The hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability | MIB7 | | |
| The Insides System for managing intestinal failure | MIB286 | | |
| The Juxta CURES adjustable compression system for treating venous leg ulcers | MIB25 | | |
| The MIST Therapy system for the promotion of wound healing | HTG267 | | |
| The NGAL Test for early diagnosis of acute kidney injury | MIB3 | | |
| The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease | MIB12 | | |
| The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer | MIB16 | | |
| The OPTIMIZER smart system for managing heart failure | MIB186 | | |
| The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies | MIB24 | | |
| The OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic joint revision | MIB13 | | |
| The PediGuard for placing pedicle screws in spinal surgery | MIB26 | | |
| The PLASMA system for transurethral resection and haemostasis of the prostate | HTG563 | | |
| The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias | MIB9 | | |
| The PressureWire fractional flow reserve measurement system for coronary artery disease | MIB2 | | |
| The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury | HTG356 | | |
| The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest | MIB4 | | |
| The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma | MIB14 | | |
| The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters | HTG368 | | |
| The Space GlucoseControl system for managing blood‑glucose in critically ill patients in intensive care | MIB17 | | |
| The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system | MIB21 | | |
| The STAK tool for preventing and treating knee stiffness | MIB252 | | |
| The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal | HTG566 | | |
| The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns | MIB1 | | |
| The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs | MIB159 | | |
| Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) | HTG124 | | |
| Therapeutic endoscopic division of epidural adhesions | HTG210 | | |
| Therapeutic hypothermia for acute ischaemic stroke | HTG511 | | |
| Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury | HTG221 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) | HTG401 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis | HTG521 | | |
| Therapeutic percutaneous image-guided aspiration of spinal cysts | HTG143 | | |
| Therapeutic sialendoscopy | HTG140 | | |
| ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation | MIB61 | | |
| Thermogard XP for therapeutic hypothermia after cardiac arrest | MIB37 | | |
| Thopaz+ portable digital system for managing chest drains | HTG465 | | |
| Thora-3Di for assessing asthma in children | MIB122 | | |
| Thoracoscopic aortopexy for severe primary tracheomalacia | HTG156 | | |
| Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation | HTG180 | | |
| Thoracoscopic excision of mediastinal parathyroid tumours | HTG159 | | |
| Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism | HTG266 | | |
| Thoracoscopic repair of congenital diaphragmatic hernia in neonates | HTG247 | | |
| Thoracoscopically assisted mitral valve surgery | HTG157 | | |
| Thrombin injections for pseudoaneurysms | HTG33 | | |
| Thyroid cancer: assessment and management | NG230 | | |
| Thyroid disease: assessment and management | NG145 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
| Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
| Tinnitus: assessment and management | NG155 | | |
| Tirzepatide for managing overweight and obesity | TA1026 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | | |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | | |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | | |
| Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium | HTG139 | | |
| Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
| Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
| TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
| Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |
| Tobacco: treating dependence | QS207 | | |
| Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
| Tocilizumab for treating giant cell arteritis | TA518 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
| Tonsillectomy using laser | HTG120 | | |
| Tonsillectomy using ultrasonic scalpel | HTG116 | | |
| TopClosure Tension Relief System for wound closure | MIB97 | | |
| Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | HTG751 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) | TA1024 | | |
| Total distal radioulnar joint replacement for symptomatic joint instability or arthritis | HTG451 | | |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
| Total prosthetic replacement of the temporomandibular joint | HTG352 | | |
| Total wrist replacement | HTG173 | | |
| Totally endoscopic robotically assisted coronary artery bypass grafting | HTG77 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| Trabecular stent bypass microsurgery for open-angle glaucoma | HTG432 | | |
| Trabeculectomy with a biodegradable collagen matrix implant for glaucoma | HTG656 | | |
| Trabeculotomy ab interno for open angle glaucoma | HTG264 | | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
| Transabdominal artificial bowel sphincter implantation for faecal incontinence | HTG177 | | |
| Transanal total mesorectal excision for rectal cancer | HTG603 | | |
| Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair | HTG593 | | |
| Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis | HTG592 | | |
| Transaxial interbody lumbosacral fusion for severe chronic low back pain | HTG478 | | |
| Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation | HTG752 | | |
| Transcatheter aortic valve implantation for aortic stenosis | HTG446 | | |
| Transcatheter endovascular closure of perimembranous ventricular septal defect | HTG213 | | |
| Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment | HTG757 | | |
| Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation | HTG631 | | |
| Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation | HTG632 | | |
| Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting | HTG415 | | |
| Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids | HTG572 | | |
| Transcranial direct current stimulation (tDCS) for depression | HTG382 | | |
| Transcranial magnetic stimulation for auditory hallucinations | HTG555 | | |
| Transcranial magnetic stimulation for obsessive-compulsive disorder | HTG548 | | |
| Transcranial magnetic stimulation for treating and preventing migraine | HTG330 | | |
| Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain | HTG491 | | |
| Transcutaneous electrical neuromuscular stimulation for urinary incontinence | HTG636 | | |
| Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine | HTG643 | | |
| Transcutaneous electrical stimulation of the trigeminal nerve for ADHD | HTG653 | | |
| Transcutaneous microwave ablation for severe primary axillary hyperhidrosis | HTG458 | | |
| Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults | HTG493 | | |
| Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine | HTG408 | | |
| Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
| Transient loss of consciousness ('blackouts') in over 16s | QS71 | | |
| Transilluminated powered phlebectomy for varicose veins | HTG16 | | |
| Transition between inpatient hospital settings and community or care home settings for adults with social care needs | NG27 | | |
| Transition between inpatient hospital settings and community or care home settings for adults with social care needs | QS136 | | |
| Transition between inpatient mental health settings and community or care home settings | NG53 | | |
| Transition between inpatient mental health settings and community or care home settings | QS159 | | |
| Transition from children's to adults' services | QS140 | | |
| Transition from children's to adults' services for young people using health or social care services | NG43 | | |
| Translaryngeal tracheostomy | HTG317 | | |
| Transmyocardial laser revascularisation for refractory angina pectoris | HTG192 | | |
| Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy | HTG337 | | |
| Transperineal biopsy for diagnosing prostate cancer | HTG680 | | |
| Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia | HTG737 | | |
| Transperineal template biopsy and mapping of the prostate | HTG237 | | |
| Transpupillary thermotherapy for age-related macular degeneration | HTG31 | | |
| Transurethral electrovaporisation of the prostate | HTG4 | | |
| Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer | HTG522 | | |
| Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG482 | | |
| Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG691 | | |
| Transvaginal laser therapy for stress urinary incontinence | HTG581 | | |
| Transvaginal laser therapy for urogenital atrophy | HTG582 | | |
| Transvaginal mesh repair of anterior or posterior vaginal wall prolapse | HTG456 | | |
| Transvenous obliteration for gastric varices | HTG658 | | |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | | |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA976 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) | TA1112 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Trauma | QS166 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| trublood-prostate for triaging and diagnosing people with prostate cancer symptoms | MIB268 | | |
| Tuberculosis | NG33 | | |
| Tuberculosis | QS141 | | |
| TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation | MIB210 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | HTG719 | | |
| Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis | HTG648 | | |
| Twin and triplet pregnancy | NG137 | | |
| TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum | MIB134 | | |
| Type 1 diabetes in adults | QS208 | | |
| Type 1 diabetes in adults: diagnosis and management | NG17 | | |
| Type 2 diabetes in adults | QS209 | | |
| Type 2 diabetes in adults: management | NG28 | | |
| Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) | ESNM65 | | |
| Type 2 diabetes prevention: population and community-level interventions | PH35 | | |
| Type 2 diabetes: insulin degludec | ESNM25 | | |
| Type 2 diabetes: insulin degludec/liraglutide (Xultophy) | ESNM60 | | |
| Type 2 diabetes: prevention in people at high risk | PH38 | | |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
| U-Drain for people needing night drainage of urine or dialysis fluid | MIB95 | | |
| Ublituximab for treating relapsing multiple sclerosis | TA1025 | | |
| Ulcerative colitis: management | NG130 | | |
| Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis | HTG375 | | |
| Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism | HTG376 | | |
| Ultrasound-guided catheterisation of the epidural space | HTG160 | | |
| Ultrasound-guided foam sclerotherapy for varicose veins | HTG301 | | |
| Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids | HTG523 | | |
| Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules | HTG416 | | |
| Ultrasound-guided regional nerve block | HTG179 | | |
| Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor | HTG474 | | |
| Unintentional injuries in the home: interventions for under 15s | PH30 | | |
| Unintentional injuries on the road: interventions for under 15s | PH31 | | |
| Unintentional injuries: prevention strategies for under 15s | PH29 | | |
| Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
| Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
| Urethrotech UCD for difficult or failed catheterisation | MIB116 | | |
| UrgoStart for treating diabetic foot ulcers and leg ulcers | HTG502 | | |
| Urinary incontinence and pelvic organ prolapse in women: management | NG123 | | |
| Urinary incontinence in neurological disease: assessment and management | CG148 | | |
| Urinary incontinence in women | QS77 | | |
| Urinary tract infection (catheter-associated): antimicrobial prescribing | NG113 | | |
| Urinary tract infection (lower): antimicrobial prescribing | NG109 | | |
| Urinary tract infection (recurrent): antimicrobial prescribing | NG112 | | |
| Urinary tract infection in children and young people | QS36 | | |
| Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
| Urinary tract infections in adults | QS90 | | |
| URO17 for detecting bladder cancer | MIB250 | | |
| UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | HTG578 | | |
| UroShield for preventing catheter-associated urinary tract infections | HTG620 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Ustekinumab for treating moderate to severe plaque psoriasis | TA180 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Uterine artery embolisation for fibroids | HTG240 | | |
| Uterine artery embolisation for treating adenomyosis | HTG324 | | |
| Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse | HTG445 | | |
| VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest | HTG765 | | |
| VA ECMO for postcardiotomy cardiogenic shock in adults | HTG762 | | |
| VA ECMO for severe acute heart failure in adults | HTG764 | | |
| VAAFT for treating anal fistulae | MIB102 | | |
| Vaccine uptake in the general population | NG218 | | |
| Vaccine uptake in under 19s | QS145 | | |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | TA1035 | | |
| Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions | HTG699 | | |
| Vagus nerve stimulation for refractory epilepsy in children | HTG25 | | |
| Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction | HTG518 | | |
| Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | TA1031 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over | TA1085 | | |
| Varenicline for smoking cessation | TA123 | | |
| Varicose veins in the legs | QS67 | | |
| Varicose veins: diagnosis and management | CG168 | | |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
| Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
| Velmanase alfa for treating alpha-mannosidosis | HST29 | | |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
| Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA1119 | | |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
| Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | NG158 | | |
| Venous thromboembolism in adults | QS201 | | |
| Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | NG89 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| Vertebral body tethering for idiopathic scoliosis in children and young people | HTG628 | | |
| VEST external stent for coronary artery bypass grafts | MIB115 | | |
| Vibegron for treating symptoms of overactive bladder syndrome | TA999 | | |
| VibraTip for testing vibration perception to detect diabetic peripheral neuropathy | HTG362 | | |
| VIDAvision for lung volume analysis in emphysema | MIB148 | | |
| Video laryngoscopes to help intubation in people with difficult airways | MIB167 | | |
| ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions | MIB295 | | |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
| Violence and aggression: short-term management in mental health, health and community settings | NG10 | | |
| Violent and aggressive behaviours in people with mental health problems | QS154 | | |
| Virtual chromoendoscopy to assess colorectal polyps during colonoscopy | HTG438 | | |
| Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment | HTG701 | | |
| Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C | HTG385 | | |
| Virtual ward platform technologies for acute respiratory infections: early value assessment | HTG697 | | |
| Visensia for early detection of deteriorating vital signs in adults in hospital | MIB36 | | |